<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00732472</url>
  </required_header>
  <id_info>
    <org_study_id>105211</org_study_id>
    <nct_id>NCT00732472</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Tolerability of Once Daily Inhaled Doses of GSK573719 Made With Magnesium Stearate in Subjects With Chronic Obstructive Pulmonary Disease(COPD)for 7 Days</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Dose Ascending, 2-cohort, Parallel Group Study to Examine the Safety, Tolerability and Pharmacokinetics of Once-daily Inhaled Doses of GSK573719 Formulated With the Excipient Magnesium Stearatein COPD Subjects for 7 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study drug which is an inhaled bronchodilator (lung airway relaxant)has been given to
      both healthy volunteers and to COPD patients before. This study will assess a new formulation
      of GSK573719. Many drugs are known to deteriorate over time. To make the study medicine less
      likely to deteriorate in its container, it is mixed with an inactive substance that helps to
      to maintain the quality of the study medicine. Previous studies have looked at GSK573719 with
      another inactive substance called Cellobiose Octaacetate (COA). This study will be looking at
      a new formulation of GSK573719 using Magnesium Stearate (MgSt) as the inactive substance.
      MgSt itself is not a medicine but is approved as a food ingredient and has also has been
      approved to be used in a number of marketed medical inhalers. The purpose of this study is to
      assess the safety and tolerability of compound GSK573719 with Magnesium Stearate for
      once-daily treatment of COPD(Chronic Obstructive Pulmonary Disease). This drug will be given
      to 2 groups of 12 people for 7 days. Group 1 will receive 250mcg or placebo and group 2 will
      receive 1000mcg or placebo. Group 2 will not be dosed until at least 6 people have completed
      dosing in group 1 without any significant safety concerns. The following safety measures will
      be assessed including: ECGs, heart rate, blood pressure, blood samples for safety labs, lung
      function and 24 hour monitoring of the heart. We will also take blood and urine samples to
      measure medication levels in the body.

      GlaxoSmithKline will be funding the research and it will be recruiting at Synexus in 7 of
      their centres in the UK.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Any On-treatment Adverse Event (AE) or Any On-treatment Serious Adverse Event (SAE)</measure>
    <time_frame>From start of treatment to study day 12</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An on-treatment adverse event is defined as an event that occurred between the start of investigational product and follow-up contact. Refer to the general SAE/non-serious AE module for a complete list of AEs reported in the study. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) on Days 1 and 7</measure>
    <time_frame>Day 1 (pre-dose and 15 minutes [min], 45 min, 1.5 hours [hr], 4 hr, and 8 hr post-dose) and Day 7 (pre-dose and 15 min, 45 min, 1.5 hr, 4 hr, 8 hr, and 24 hr post-dose)</time_frame>
    <description>Blood pressure was measured in a semi-recumbent position at approximately 45 degrees after the participant was kept at rest for at least 5 minutes. SBP and DBP were obtained at pre-dose and 15 min, 45 min, 1.5 hr, 4 hr, and 8 hr post-dose (PD) on Day 1 and at pre-dose and 15 min, 45 min, 1.5 hr, 4 hr, 8 hr, and 24 hr PD on Day 7.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Heart Rate (HR) on Days 1 and 7</measure>
    <time_frame>Day 1 (pre-dose and 15 minutes [min], 45 min, 1.5 hours [hr], 4 hr, and 8 hr post-dose) and Day 7 (pre-dose and 15 min, 45 min, 1.5 hr, 4 hr, 8 hr, and 24 hr post-dose)</time_frame>
    <description>HR was measured in a semi-recumbent position at approximately 45 degrees after the participant was kept at rest for at least 5 minutes. HR was obtained at pre-dose and 15 min, 45 min, 1.5 hr, 4 hr, and 8 hr post-dose (PD) on Day 1 and at pre-dose and 15 min, 45 min, 1.5 hr, 4 hr, 8 hr, and 24 hr PD on Day 7.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum and Weighted Mean (0-4 Hour) Heart Rate at Days 1 and 7</measure>
    <time_frame>Day 1 and Day 7</time_frame>
    <description>Maximum heart rate (Max HR) and weighted mean (WM) from 0-4 hour on Days 1 and 7 were derived. Max HR (0-4 h) is defined as the maximum heart rate attained within 0-4 h. The weighted mean HR (0-4 h) was derived by calculating the area under the curve, and then dividing the value by the relevant time interval. Each of the maximum and weighted mean (0-4h) endpoints for heart rate, was statistically analyzed using a mixed effects model. The terms treatment, baseline, day and any relevant interactions were considered in the model. Least squares means are adjusted for treatment, Baseline, day, treatment by Baseline and Baseline by day interaction, where Baseline is defined as the mean of the three pre-dose assessments.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With the Indicated 12-lead Electrocardiogram (ECG) Values on Days 1 and 7</measure>
    <time_frame>Day 1 (pre-dose and 15 min, 45 min, 1.5 hr, 4 hr, and 8 hr post-dose) and Day 7 (pre-dose and 15 min, 45 min, 1.5 hr, 4 hr, 8 hr, and 24 hr)</time_frame>
    <description>The number of participants with normal (NL), abnormal not clinically significant (Abn NCS), and abnormal clinically significant (Abn CS) ECG findings, as well as those with unavailable results (NA) at pre-dose (PD1, PD2, PD3), and 15 min, 45 min, 1.5 hr, 4 hr, and 8 hr post-dose (PD) on Day 1 and at pre-dose (PD1, PD2, PD3), and 15 min, 45 min, 1.5 hr, 4 hr, 8 hr, and 24 hr post-dose on Day 7 are reported. The following are of potential clinical importance: absolute QTc interval &gt;450 milliseconds (msec); increase from Baseline QTc &gt;60 msec; PR interval &lt;110 and &gt;220 msec; QRS interval &lt;75 and &gt;110 msec. Clinical significance was based on the medical and scientific judgement of the investigator or qualified designee.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal 24-hour Holter Findings at Screening and Day 7</measure>
    <time_frame>Screening and Day 7</time_frame>
    <description>Twenty-four hour Holter ECG values were obtained at Screening and on Day 7. During the Screening procedure and study, standard Holter monitors were used (in order to exclude participants with underlying cardiac arrhythmogenicity). During the treatment periods, Holter monitors were only switched on immediately prior to dosing (up to 15 minutes pre-dose) so as to capture Holter ECG data from the 24 hour period following dosing. The following summary data were transcribed into the Case Report Form: Maximum and mean (0 to24 hour) heart rate; normal and aberrant beats and arrhythmias. Analysis of the Holter tapes was arranged by GlaxoSmithKline.The number of participants with normal (NL), abnormal not clinically significant (Abn NCS), and abnormal clinically significant (Abn CS) ECG findings, as well as those with unavailable results (NA) at Screening and Day 7, are reported. Clinical significance was based on the medical and scientific judgement of the investigator or qualified designee.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum and Mean (0-24 Hour) Heart Rate From Holter Monitoring on Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Maximum heart rate (Max HR) and mean HR from 0-24 hour Holter monitoring on treatment Day 7 were derived. The analysis was adjusted for treatment and Baseline, where Baseline is defined as the corresponding summary measure (i.e., mean heart rate [0-24 hours] or maximum heart rate [0-24 hours]) from screening records.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Forced Expiratory Volume in One Second (FEV1) at Screening and on Days 1 and 7</measure>
    <time_frame>Screening, Day 1, and Day 7</time_frame>
    <description>FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 was measured at Screening, pre-dose, and 4 hours (hr) post-dose on Day 1 and Day 7. FEV1 tests were repeated until three technically acceptable measurements were made.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Number of Salbutamol Doses Taken Over the 7 -Day Study Period</measure>
    <time_frame>Day 1 to Day 7</time_frame>
    <description>The total number of salbutamol doses taken per day was recorded by the participants in their dairy card over the entire 7-day treatment period. Diaries were reviewed by the Investigator when participants were admitted to the unit on Day 1, Day 7, and Day 8. Salbutamol was given as rescue medication, defined as a quick-relief or fast-acting medication that is given in addition to the investigational drug or placebo that can alleviate symptoms due to disease or lack of efficacy of the study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Albumin, Total Protein, Hemoglobin, and Mean Corpuscle Hemoglobin Concentration (MCHC) Values on Day 1 and Day 7</measure>
    <time_frame>Day 1 and Day 7</time_frame>
    <description>Blood samples were collected for the measurement of albumin, total protein, hemoglobin, and MCHC values pre-dose on Day 1 and Day 7.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) Values on Day1 and Day 7</measure>
    <time_frame>Day 1 and Day 7</time_frame>
    <description>Blood samples were collected for the measurement of ALP, ALT, AST, and GGT Pre-dose on Day 1 and Day 7.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Direct Bilirubin, Total Bilirubin, and Creatinine Values on Day 1 and Day 7</measure>
    <time_frame>Day 1 and Day 7</time_frame>
    <description>Blood samples were collected for the measurement of direct bilirubin, total bilirubin, and creatinine at pre-dose on Day 1 and Day 7.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Calcium, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) Values on Day 1 and Day 7</measure>
    <time_frame>Day 1 and Day 7</time_frame>
    <description>Blood samples were collected for the measurement of calcium, glucose, potassium, sodium, and urea/BUN pre-dose on Day 1 and Day 7.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Basophil, Eosinophil, Lymphocyte, Monocyte, Total Neutrophil (ANC: Absolute Neutrophil Count), Platelet, and White Blood Cell (WBC) Count Values on Day 1 and Day 7</measure>
    <time_frame>Day 1 and Day 7</time_frame>
    <description>Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, total neutrophils (ANC), platelets, and white blood cell (WBC) count pre-dose on Day 1 and Day 7.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Corpuscle Hemoglobin (MCH) Values on Day 1 and Day 7</measure>
    <time_frame>Day 1 and Day 7</time_frame>
    <description>Blood samples were collected for the measurement of MCH pre-dose on Day 1 and Day 7.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Corpuscle Volume (MCV) Values on Day 1 and Day 7</measure>
    <time_frame>Day 1 and Day 7</time_frame>
    <description>Blood samples were collected for the measurement of MCV pre-dose on Day 1 and Day 7.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean AUC(0-2), AUC(0-8), and AUC(0-t) of UMEC on Day 1 and Day 7</measure>
    <time_frame>Day 1 and Day 7: pre-dose, and 5 min, 15 min, 30 min, 1 hr, 2 hr, 4 hr, and 8 hr post-dose; 24 hr post-dose on Day 7</time_frame>
    <description>Area under the concentration-time (AUC) curve from time zero (pre-dose) to 2 hours (AUC[0-2]), from time zero to 8 hours (AUC[0-8]), from time zero to the last time of a quantifiable concentration of UMEC (AUC[0-t]) on Day 1 and Day 7 were measured. AUC is a measure of systemic exposure. Blood samples were collected pre-dose and 5 min, 15 min, 30 min, 1 hr, 2 hr, 4 hr, and 8 hr post-dose on Day 1 and Day 7. Also, a 24 hr blood sample was collected on Day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of UMEC on Day 1 and Day 7</measure>
    <time_frame>Day 1 and Day 7: pre-dose, and 5 min, 15 min, 30 min, 1 hr, 2 hr, 4 hr, and 8 hr post-dose; 24 hr post-dose on Day 7</time_frame>
    <description>Cmax is defined as the maximum observed concentration of UMEC and was measured on Day 1 and Day 7. Blood samples were collected pre-dose and 5 min, 15 min, 30 min, 1 hr, 2 hr, 4 hr, and 8 hr post-dose on Day 1 and Day 7. Also, a 24 hr blood sample was collected on Day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax and Tlastof UMEC on Day 1 and Day 7</measure>
    <time_frame>Day 1 and Day 7: pre-dose, and 5 min, 15 min, 30 min, 1 hr, 2 hr, 4 hr, and 8 hr post-dose; 24 hr post-dose on Day 7</time_frame>
    <description>Tmax is defined as the time to reach the observed maximum concentration, and tlast is defined as the time of the last quantifiable concentration of UMEC; both were measured on Day 1 and Day 7. Blood samples were collected pre-dose, and 5 min, 15 min, 30 min, 1 hr, 2 hr, 4 hr, and 8 hr post-dose on Day 1 and Day 7. Also, a 24 hr blood sample was collected on Day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae(0-4), Ae(0-8), Ae(0-12), and Ae(0-24) of UMEC on Day 1 and Day 7</measure>
    <time_frame>From 0-8 hours (hr), 8-12 hr, and 12-24 hr on Day 1; from 0-4 hr, 4-8 hr, 8-12 hr, and 12-24 hr on Day 7</time_frame>
    <description>Urinary recovery of unchanged drug (UMEC) within the first 8, 12, and 24 hours (Ae[0-8], Ae[0-12], and Ae[0-24], respectively) on Day 1 and within the first 4, 8, 12, and 24 hours (Ae[0-4], Ae[0-8], Ae[0-12], and Ae[0-24], respectively) on Day 7 was estimated. Urine samples were collected from 0-8 hours (hr), 8-12 hr, and 12-24 hr on Day 1 and from 0-4 hr, 4-8 hr, 8-12 hr, and 12-24 hr on Day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fe(0-4), Fe(0-8), Fe(0-12), and Fe(0-24) of UMEC on Day 1 and Day 7</measure>
    <time_frame>From 0-8 hours (hr), 8-12 hr, and 12-24 hr on Day 1; from 0-4 hr, 4-8 hr, 8-12 hr, and 12-24 hr on Day 7</time_frame>
    <description>The fraction of the total dose excreted (Fe) in each interval was estimated as the urinary recovery of unchanged drug (Ae) per dose. Urine samples were collected from 0-8 hours (hr), 8-12 hr, and 12-24 hr on Day 1 and from 0-4 hr, 4-8 hr, 8-12 hr, and 12-24 hr on Day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Clearance of UMEC on Day 1 and Day 7</measure>
    <time_frame>From 0-8 hours (hr), 8-12 hr, and 12-24 hr on Day 1; from 0-4 hr, 4-8 hr, 8-12 hr, and 12-24 hr on Day 7</time_frame>
    <description>Renal clearance was calculated as the urinary recovery of unchanged drug from time zero to time x (Ae[0-x])/area under concentration from time zero to time x (AUC[0-x]) for the longest period of time after dosing when both could be accurately determined (where x is either 8, 12, or 24). Urine samples were collected from 0-8 hours (hr), 8-12 hr, and 12-24 hr on Day 1 and from 0-4 hr, 4-8 hr, 8-12 hr, and 12-24 hr on Day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Half Life (t1/2) of UMEC on Day 7</measure>
    <time_frame>From 0-4 hours (hr), 4-8 hr, 8-12 hr, and 12-24 hr on Day 7</time_frame>
    <description>Urine half life (t1/2) of UMEC on Day 7 was estimated. Urine samples were collected from 0-4 hours (hr), 4-8 hr, 8-12 hr, and 12-24 hr on Day 7.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>7 day repeat dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7 day repeat dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK573719</intervention_name>
    <description>7 day repeat dose</description>
    <arm_group_label>7 day repeat dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between 40 and 75 years of age

          -  A female subject is eligible to participate if she is of:

               -  Non childbearing potential including pre-menopausal females with documented
                  (medical report verification) hysterectomy, bilateral salpingectomy or bilateral
                  oophorectomy or postmenopausal defined as 12 months of spontaneous amenorrhea or
                  6 months of spontaneous amenorrhea with serum FSH levels &gt; 40 mIU/mL and
                  estradiol &lt; 40 pg/ml (&lt;140 pmol/L) or 6 weeks postsurgical bilateral oophorectomy
                  with or without hysterectomy.

          -  Male subjects must agree to use one of the listed contraception methods. This
             criterion must be followed from the time of the first dose of study medication until
             90 days post-last dose.

          -  Subject diagnosed with COPD, as defined by the GOLD guidelines.

          -  BMI within the range 18 - 34 kg/m2 (inclusive).

          -  Subject is a smoker or an ex-smoker with a smoking history of at least 10 pack years
             (Pack years = (cigarettes per day smoked/20) x number of years smoked)).

          -  Average QTcB or QTcF ≤ 450 msec taken from triplicate assessments at screening; or QTc
             ≤ 480 msec in subjects with Bundle Branch Block.

          -  Subject has a post-bronchodilator (400 μg salbutamol) FEV1 of ≥ 35% to ≤ 80% of
             predicted normal.

          -  Subject has FEV1/FVC &lt; 0.7 post-bronchodilator (400 μg salbutamol).

          -  Subjects have a 24hour holter recording that is within normal limits for the
             individual and does not demonstrate any clinically important abnormality that, in the
             opinion of the investigator, would make the subject unsuitable for participation in
             the study.

          -  Capable of giving written informed consent, which includes compliance with the
             requirements and restrictions listed in the consent form.

          -  Subject is available to complete all study measurements and procedures.

        Exclusion Criteria:

          -  Subjects who have a past or present disease, which as judged by the Investigator, may
             affect subject safety or influence the outcome of the study.

          -  The subject has a positive pre-study drug/alcohol screen. A minimum list of drugs that
             will be screened for include amphetamines, barbiturates, cocaine and opiates.

        The detection of drugs taken for a legitimate medical purpose would not necessarily be an
        exclusion to study participation. The detection of alcohol would not be an exclusion at
        screening but would need to be negative pre-dose and during the study.

          -  Female subject has a positive pregnancy test.

          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody
             result within 3 months of screening.

          -  A positive test for HIV antibody (if tested, according to local SOP's).

          -  History of high alcohol consumption within 1 month of the study defined as:

               -  an average weekly intake of greater than 21 units or an average daily intake of
                  greater than 3 units (males), or defined as an average weekly intake of greater
                  than 14 units or an average daily intake of greater than 2 units (females). One
                  unit is equivalent to a half-pint (220mL) of beer or 1 (25ml) measure of spirits
                  or 1 glass (125ml) of wine.

          -  The subject has participated in a clinical trial and has received an investigational
             product within the following time period prior to the first dosing day in the current
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the
             investigational product (whichever is longer).

          -  Exposure to more than four new chemical entities within 12 months prior to the first
             dosing day.

          -  History of sensitivity to any of the study medications, or components thereof
             (including allergy to milk protein/lactose) or a history of drug or other allergy
             that, in the opinion of the Investigator or GSK Medical Monitor, contraindicates their
             participation.

          -  Subject has donated a unit (400 mL) of blood within 60 days of screening or, intends
             to donate during the study.

          -  Where participation in the study would result in donation of blood or blood products
             in excess of 500 mL within a 56 day period.

          -  Unwillingness or inability to follow the procedures outlined in the protocol.

          -  The subject is unable to use the novel dry powder inhaler correctly.

          -  The subject requires treatment for prostate hypertrophy.

          -  The subject has a history of narrow angle glaucoma.

        Respiratory criteria

          -  Subject has a diagnosis of active tuberculosis, lung cancer, clinically overt
             bronchiectasis, pulmonary fibrosis, asthma or any other respiratory condition that
             might, in the opinion of the Investigator, compromise the safety of the subject or
             affect the interpretation of the results.

          -  Subject has poorly controlled COPD, defined as the occurrence of any of the following:

               -  Either: acute worsening of COPD that is managed by the subject at home requiring
                  treatment with corticosteroids in the 2 weeks prior to the screening visit.

               -  Or: more than two exacerbations in the previous 4 months prior to the screening
                  visit that required a course of oral corticosteroids or, for which the subject
                  was hospitalised.

          -  Subject has had a respiratory tract infection in the 2 weeks prior to first dose.

        Cardiovascular criteria

          -  Current congestive heart failure (greater than NYHA II) and myocardial infarction
             (within 9 months of the screening date).

          -  A history of clinically significant arrhythmia or clinically important 24 h Holter
             findings that, in the opinion of the Investigator, would cause a safety concern for
             entry into the study.

          -  A mean QTc(B) value at screening &gt;450msec, or an ECG that is not suitable for QT
             measurements (e.g. LBBB or poorly defined termination of the T wave).

          -  Third degree heart block or pacemaker.

          -  Risk factors for torsades des pointes (heart failure NYHA II-IV, familial long QT
             syndrome).

          -  Elevated resting blood pressure or a mean blood pressure equal to or higher than
             150/90 mmHg at screening. A history of and treatment for hypertension is acceptable
             provided control has been achieved for &gt; 2 months prior to screening.

          -  A mean heart rate outside the range 50-100 bpm at screening.

        Concurrent medication criteria

          -  Subject requires treatment with nebulised beta-2 agonist or nebulised
             anticholinergics.

          -  Subject has received oral or parenteral corticosteroids within 2 weeks of screening.

          -  Subject is unable to abstain from long-acting bronchodilators from 48 hours prior to
             the screening and treatment periods (i.e. the last assessment in the dosing period).

        (Note, subjects may resume use of their usual medication in between screening and the
        treatment period if the restrictions in Section 9 Concomitant Medications and Non-Drug
        Therapies are followed and provided the long acting bronchodilator component is stopped
        again 48h or more prior to dosing).

          -  Subject is receiving co-medication with drugs which are commonly recognised to prolong
             the QTc interval (e.g. quinolones, amiodorane, disopyramide, quinidine, sotalol,
             chlorpromazine, haloperidol, ketoconazole, terfenadine, cisapride and terodiline).

          -  Subject requires regular treatment with oral corticosteroids (prednisolone or
             equivalent).

          -  Subject is receiving treatment with beta-blockers, except eye drops.

          -  Subject is receiving treatment with long-term or short-term oxygen therapy, NIPPV or
             requires nocturnal positive pressure for sleep apnea.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Reading</city>
        <state>Berkshire</state>
        <zip>RG2 0TG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buckshaw Village, Chorley</city>
        <state>Lancashire</state>
        <zip>PR7 7NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Waterloo, Liverpool</city>
        <state>Merseyside</state>
        <zip>L22 0LG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clydebank, Glasgow</city>
        <zip>G81 2DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edgbaston, Birmingham</city>
        <zip>B15 2SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Llanishen</city>
        <zip>CF14 5GJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M15 6SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Tal-Singer R, Cahn A, Mehta R, Preece A, Crater G, Kelleher D, Pouliquen IJ. Initial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: two randomised studies. Eur J Pharmacol. 2013 Feb 15;701(1-3):40-8. doi: 10.1016/j.ejphar.2012.12.019. Epub 2012 Dec 28.</citation>
    <PMID>23276660</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2008</study_first_submitted>
  <study_first_submitted_qc>August 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2008</study_first_posted>
  <results_first_submitted>January 2, 2014</results_first_submitted>
  <results_first_submitted_qc>January 2, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 17, 2014</results_first_posted>
  <last_update_submitted>October 11, 2016</last_update_submitted>
  <last_update_submitted_qc>October 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease (COPD)</keyword>
  <keyword>Magnesium stearate</keyword>
  <keyword>GSK573719</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>105211</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>105211</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>105211</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>105211</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>105211</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>105211</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>105211</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants=par.; umeclidinium=UMEC. A total of 37 unique par. were enrolled in the study; however, 1 par. was randomized and dosed on two separate occasions and is counted as two separate par. on all outputs (thus, 38 par. started study treatment).</recruitment_details>
      <pre_assignment_details>Participants were assigned to one of two cohorts: UMEC 250 micrograms (μg) once daily (QD) or placebo (Cohort 1) and UMEC 1000 μg QD or placebo (Cohort 2) for 7 days. After reporting of Cohorts 1 and 2, it was found that par. in Cohort 2 received UMEC 250 μg in error. Cohort 3 was then recruited, in which par. received UMEC 1000 μg QD or placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received either a single inhaled dose or four inhaled doses of matching placebo once daily (QD) for 7 days via a dry powder inhaler (DPI).</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1 UMEC 250 µg</title>
          <description>Participants received a single inhaled dose of umeclidinium (UMEC) 250 micrograms (µg) formulated with magnesium stearate (MgSt) QD for 7 days via a DPI.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 2 UMEC 250 µg in Error</title>
          <description>Participants received a single inhaled dose of UMEC 250 μg formulated with MgSt QD for 7 days via a DPI. These participants were to have been randomized to receive UMEC 1000 µg; however, they received UMEC 250 µg in error.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 3 UMEC 1000 µg</title>
          <description>Participants received four inhaled doses of UMEC 250 μg (equivalent to 1000 μg) formulated with MgSt QD for 7 days via a DPI.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10">One par. (counted as 2 on outputs) was randomized/dosed with UMEC 250 µg on 2 separate occasions.</participants>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received either a single inhaled dose or four inhaled doses of matching placebo once daily (QD) for 7 days via a dry powder inhaler (DPI).</description>
        </group>
        <group group_id="B2">
          <title>Cohort 1 UMEC 250 µg</title>
          <description>Participants received a single inhaled dose of umeclidinium (UMEC) 250 micrograms (µg) formulated with magnesium stearate (MgSt) QD for 7 days via a DPI.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 2 UMEC 250 µg in Error</title>
          <description>Participants received a single inhaled dose of UMEC 250 μg formulated with MgSt QD for 7 days via a DPI. These participants were to have been randomized to receive UMEC 1000 µg; however, they received UMEC 250 µg in error.</description>
        </group>
        <group group_id="B4">
          <title>Cohort 3 UMEC 1000 µg</title>
          <description>Participants received four inhaled doses of UMEC 250 μg (equivalent to 1000 μg) formulated with MgSt QD for 7 days via a DPI.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.2" spread="4.47"/>
                    <measurement group_id="B2" value="63.3" spread="8.21"/>
                    <measurement group_id="B3" value="64.7" spread="6.31"/>
                    <measurement group_id="B4" value="64.2" spread="7.97"/>
                    <measurement group_id="B5" value="64.6" spread="6.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White - White/Caucasian/European Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Any On-treatment Adverse Event (AE) or Any On-treatment Serious Adverse Event (SAE)</title>
        <description>An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An on-treatment adverse event is defined as an event that occurred between the start of investigational product and follow-up contact. Refer to the general SAE/non-serious AE module for a complete list of AEs reported in the study. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect.</description>
        <time_frame>From start of treatment to study day 12</time_frame>
        <population>All Subjects Population: all participants who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received either a single inhaled dose or four inhaled doses of matching placebo once daily (QD) for 7 days via a dry powder inhaler (DPI).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 UMEC 250 µg</title>
            <description>Participants received a single inhaled dose of umeclidinium (UMEC) 250 micrograms (µg) formulated with magnesium stearate (MgSt) QD for 7 days via a DPI.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 UMEC 250 µg in Error</title>
            <description>Participants received a single inhaled dose of UMEC 250 μg formulated with MgSt QD for 7 days via a DPI. These participants were to have been randomized to receive UMEC 1000 µg; however, they received UMEC 250 µg in error.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3 UMEC 1000 µg</title>
            <description>Participants received four inhaled doses of UMEC 250 μg (equivalent to 1000 μg) formulated with MgSt QD for 7 days via a DPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any On-treatment Adverse Event (AE) or Any On-treatment Serious Adverse Event (SAE)</title>
          <description>An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An on-treatment adverse event is defined as an event that occurred between the start of investigational product and follow-up contact. Refer to the general SAE/non-serious AE module for a complete list of AEs reported in the study. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect.</description>
          <population>All Subjects Population: all participants who received at least one dose of study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any on-treatment AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any on-treatment SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) on Days 1 and 7</title>
        <description>Blood pressure was measured in a semi-recumbent position at approximately 45 degrees after the participant was kept at rest for at least 5 minutes. SBP and DBP were obtained at pre-dose and 15 min, 45 min, 1.5 hr, 4 hr, and 8 hr post-dose (PD) on Day 1 and at pre-dose and 15 min, 45 min, 1.5 hr, 4 hr, 8 hr, and 24 hr PD on Day 7.</description>
        <time_frame>Day 1 (pre-dose and 15 minutes [min], 45 min, 1.5 hours [hr], 4 hr, and 8 hr post-dose) and Day 7 (pre-dose and 15 min, 45 min, 1.5 hr, 4 hr, 8 hr, and 24 hr post-dose)</time_frame>
        <population>All Subjects Population (ASP). Only participants with data available at the indicated time points were summarized. Different participants may have been summarized for different parameters/at different time points (reflected by n=X, X, X, X in the category titles), so the overall number of participants summarized reflects everyone in the ASP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received either a single inhaled dose or four inhaled doses of matching placebo once daily (QD) for 7 days via a dry powder inhaler (DPI).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 UMEC 250 µg</title>
            <description>Participants received a single inhaled dose of umeclidinium (UMEC) 250 micrograms (µg) formulated with magnesium stearate (MgSt) QD for 7 days via a DPI.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 UMEC 250 µg in Error</title>
            <description>Participants received a single inhaled dose of UMEC 250 μg formulated with MgSt QD for 7 days via a DPI. These participants were to have been randomized to receive UMEC 1000 µg; however, they received UMEC 250 µg in error.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3 UMEC 1000 µg</title>
            <description>Participants received four inhaled doses of UMEC 250 μg (equivalent to 1000 μg) formulated with MgSt QD for 7 days via a DPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) on Days 1 and 7</title>
          <description>Blood pressure was measured in a semi-recumbent position at approximately 45 degrees after the participant was kept at rest for at least 5 minutes. SBP and DBP were obtained at pre-dose and 15 min, 45 min, 1.5 hr, 4 hr, and 8 hr post-dose (PD) on Day 1 and at pre-dose and 15 min, 45 min, 1.5 hr, 4 hr, 8 hr, and 24 hr PD on Day 7.</description>
          <population>All Subjects Population (ASP). Only participants with data available at the indicated time points were summarized. Different participants may have been summarized for different parameters/at different time points (reflected by n=X, X, X, X in the category titles), so the overall number of participants summarized reflects everyone in the ASP.</population>
          <units>Millimeters of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP, Day 1, pre-dose, n=9, 10, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.9" spread="11.43"/>
                    <measurement group_id="O2" value="132.8" spread="11.97"/>
                    <measurement group_id="O3" value="137.4" spread="10.71"/>
                    <measurement group_id="O4" value="138.6" spread="19.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 1, 15 min PD, n=9, 9, 10, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.1" spread="12.96"/>
                    <measurement group_id="O2" value="134.9" spread="15.05"/>
                    <measurement group_id="O3" value="137.7" spread="9.94"/>
                    <measurement group_id="O4" value="135.0" spread="14.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 1, 45 min PD, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.3" spread="9.35"/>
                    <measurement group_id="O2" value="135.8" spread="14.63"/>
                    <measurement group_id="O3" value="133.9" spread="11.28"/>
                    <measurement group_id="O4" value="140.1" spread="17.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 1, 1.5 hr PD, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.0" spread="19.42"/>
                    <measurement group_id="O2" value="138.2" spread="15.79"/>
                    <measurement group_id="O3" value="142.1" spread="12.91"/>
                    <measurement group_id="O4" value="145.0" spread="21.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 1, 4 hr PD, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.0" spread="15.41"/>
                    <measurement group_id="O2" value="139.4" spread="21.43"/>
                    <measurement group_id="O3" value="141.6" spread="8.86"/>
                    <measurement group_id="O4" value="138.9" spread="11.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 1, 8 hr PD, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.8" spread="12.22"/>
                    <measurement group_id="O2" value="135.7" spread="15.28"/>
                    <measurement group_id="O3" value="140.8" spread="13.14"/>
                    <measurement group_id="O4" value="146.2" spread="14.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 7, pre-dose, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.3" spread="9.16"/>
                    <measurement group_id="O2" value="131.8" spread="14.47"/>
                    <measurement group_id="O3" value="139.3" spread="10.59"/>
                    <measurement group_id="O4" value="120.2" spread="10.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 7, 15 min PD, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.3" spread="13.95"/>
                    <measurement group_id="O2" value="134.4" spread="15.54"/>
                    <measurement group_id="O3" value="138.8" spread="12.67"/>
                    <measurement group_id="O4" value="127.5" spread="14.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 7, 45 min PD, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.7" spread="13.93"/>
                    <measurement group_id="O2" value="135.4" spread="19.08"/>
                    <measurement group_id="O3" value="135.8" spread="9.28"/>
                    <measurement group_id="O4" value="126.3" spread="14.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 7, 1.5 hr PD, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.8" spread="15.34"/>
                    <measurement group_id="O2" value="141.6" spread="18.35"/>
                    <measurement group_id="O3" value="141.3" spread="10.9"/>
                    <measurement group_id="O4" value="130.2" spread="10.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 7, 4 hr PD, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.4" spread="12.91"/>
                    <measurement group_id="O2" value="139.6" spread="15.18"/>
                    <measurement group_id="O3" value="141.6" spread="8.56"/>
                    <measurement group_id="O4" value="135.0" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 7, 8 hr PD, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.1" spread="13.17"/>
                    <measurement group_id="O2" value="129.4" spread="14.32"/>
                    <measurement group_id="O3" value="136.1" spread="13.7"/>
                    <measurement group_id="O4" value="125.7" spread="8.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 7, 24 hr PD, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.1" spread="9.49"/>
                    <measurement group_id="O2" value="135.7" spread="9.39"/>
                    <measurement group_id="O3" value="136.0" spread="9.82"/>
                    <measurement group_id="O4" value="127.5" spread="7.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 1, pre-dose, n=9, 10, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.6" spread="8.52"/>
                    <measurement group_id="O2" value="79.0" spread="6.69"/>
                    <measurement group_id="O3" value="82.1" spread="7.63"/>
                    <measurement group_id="O4" value="82.4" spread="5.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 1, 15 min PD, n=9, 9, 10, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.6" spread="9.76"/>
                    <measurement group_id="O2" value="83.6" spread="7.47"/>
                    <measurement group_id="O3" value="81.4" spread="7.71"/>
                    <measurement group_id="O4" value="85.8" spread="10.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 1, 45 min PD, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.9" spread="8.85"/>
                    <measurement group_id="O2" value="79.6" spread="9.58"/>
                    <measurement group_id="O3" value="82.8" spread="9.96"/>
                    <measurement group_id="O4" value="83.8" spread="7.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 1, 1.5 hr PD, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.3" spread="8.54"/>
                    <measurement group_id="O2" value="82.3" spread="9.26"/>
                    <measurement group_id="O3" value="84.0" spread="6.55"/>
                    <measurement group_id="O4" value="85.4" spread="6.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 1, 4 hr PD, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.4" spread="11.14"/>
                    <measurement group_id="O2" value="81.0" spread="10.91"/>
                    <measurement group_id="O3" value="83.1" spread="11.13"/>
                    <measurement group_id="O4" value="83.7" spread="6.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 1, 8 hr PD, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" spread="8.67"/>
                    <measurement group_id="O2" value="79.9" spread="8.85"/>
                    <measurement group_id="O3" value="80.5" spread="7.84"/>
                    <measurement group_id="O4" value="85.3" spread="6.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 7, pre-dose, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.7" spread="8.64"/>
                    <measurement group_id="O2" value="82.6" spread="8.85"/>
                    <measurement group_id="O3" value="85.8" spread="7.79"/>
                    <measurement group_id="O4" value="76.5" spread="4.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 7, 15 min PD, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.8" spread="11.78"/>
                    <measurement group_id="O2" value="82.7" spread="9.11"/>
                    <measurement group_id="O3" value="82.9" spread="9.29"/>
                    <measurement group_id="O4" value="81.8" spread="5.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 7, 45 min PD, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.6" spread="10.36"/>
                    <measurement group_id="O2" value="81.4" spread="9.45"/>
                    <measurement group_id="O3" value="82.4" spread="7.04"/>
                    <measurement group_id="O4" value="81.8" spread="6.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 7, 1.5 hr PD, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.2" spread="9.91"/>
                    <measurement group_id="O2" value="82.6" spread="8.90"/>
                    <measurement group_id="O3" value="83.1" spread="9.97"/>
                    <measurement group_id="O4" value="81.7" spread="3.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 7, 4 hr PD, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.0" spread="8.97"/>
                    <measurement group_id="O2" value="84.0" spread="7.68"/>
                    <measurement group_id="O3" value="83.0" spread="8.09"/>
                    <measurement group_id="O4" value="81.0" spread="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 7, 8 hr PD, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2" spread="8.70"/>
                    <measurement group_id="O2" value="77.1" spread="11.51"/>
                    <measurement group_id="O3" value="80.7" spread="7.45"/>
                    <measurement group_id="O4" value="77.8" spread="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 7, 24 hr PD, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.2" spread="8.87"/>
                    <measurement group_id="O2" value="81.6" spread="9.05"/>
                    <measurement group_id="O3" value="81.7" spread="9.70"/>
                    <measurement group_id="O4" value="79.8" spread="4.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Heart Rate (HR) on Days 1 and 7</title>
        <description>HR was measured in a semi-recumbent position at approximately 45 degrees after the participant was kept at rest for at least 5 minutes. HR was obtained at pre-dose and 15 min, 45 min, 1.5 hr, 4 hr, and 8 hr post-dose (PD) on Day 1 and at pre-dose and 15 min, 45 min, 1.5 hr, 4 hr, 8 hr, and 24 hr PD on Day 7.</description>
        <time_frame>Day 1 (pre-dose and 15 minutes [min], 45 min, 1.5 hours [hr], 4 hr, and 8 hr post-dose) and Day 7 (pre-dose and 15 min, 45 min, 1.5 hr, 4 hr, 8 hr, and 24 hr post-dose)</time_frame>
        <population>All Subjects Population. Only participants with data available at the indicated time points were summarized. Different participants may have been summarized for different parameters/at different time points (reflected by n=X, X, X, X in the category titles), so the overall number of participants summarized reflects everyone in the ASP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received either a single inhaled dose or four inhaled doses of matching placebo once daily (QD) for 7 days via a dry powder inhaler (DPI).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 UMEC 250 µg</title>
            <description>Participants received a single inhaled dose of umeclidinium (UMEC) 250 micrograms (µg) formulated with magnesium stearate (MgSt) QD for 7 days via a DPI.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 UMEC 250 µg in Error</title>
            <description>Participants received a single inhaled dose of UMEC 250 μg formulated with MgSt QD for 7 days via a DPI. These participants were to have been randomized to receive UMEC 1000 µg; however, they received UMEC 250 µg in error.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3 UMEC 1000 µg</title>
            <description>Participants received four inhaled doses of UMEC 250 μg (equivalent to 1000 μg) formulated with MgSt QD for 7 days via a DPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Heart Rate (HR) on Days 1 and 7</title>
          <description>HR was measured in a semi-recumbent position at approximately 45 degrees after the participant was kept at rest for at least 5 minutes. HR was obtained at pre-dose and 15 min, 45 min, 1.5 hr, 4 hr, and 8 hr post-dose (PD) on Day 1 and at pre-dose and 15 min, 45 min, 1.5 hr, 4 hr, 8 hr, and 24 hr PD on Day 7.</description>
          <population>All Subjects Population. Only participants with data available at the indicated time points were summarized. Different participants may have been summarized for different parameters/at different time points (reflected by n=X, X, X, X in the category titles), so the overall number of participants summarized reflects everyone in the ASP.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, pre-dose, n=9, 10, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.9" spread="11.09"/>
                    <measurement group_id="O2" value="68.3" spread="10.42"/>
                    <measurement group_id="O3" value="72.8" spread="11.69"/>
                    <measurement group_id="O4" value="64.7" spread="10.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 15 min PD, n=9, 9, 10, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.2" spread="10.28"/>
                    <measurement group_id="O2" value="67.4" spread="11.28"/>
                    <measurement group_id="O3" value="71.4" spread="9.86"/>
                    <measurement group_id="O4" value="72.3" spread="13.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 45 min PD, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.0" spread="9.33"/>
                    <measurement group_id="O2" value="62.3" spread="10.90"/>
                    <measurement group_id="O3" value="70.2" spread="11.95"/>
                    <measurement group_id="O4" value="66.4" spread="14.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1.5 hr PD, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.3" spread="9.42"/>
                    <measurement group_id="O2" value="60.7" spread="12.06"/>
                    <measurement group_id="O3" value="65.8" spread="10.30"/>
                    <measurement group_id="O4" value="64.2" spread="11.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4 hr PD, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.0" spread="10.37"/>
                    <measurement group_id="O2" value="62.0" spread="10.31"/>
                    <measurement group_id="O3" value="70.2" spread="10.74"/>
                    <measurement group_id="O4" value="65.7" spread="10.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 8 hr PD, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.6" spread="9.93"/>
                    <measurement group_id="O2" value="67.4" spread="9.62"/>
                    <measurement group_id="O3" value="77.2" spread="11.73"/>
                    <measurement group_id="O4" value="74.4" spread="7.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, pre-dose, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.1" spread="7.90"/>
                    <measurement group_id="O2" value="71.3" spread="12.64"/>
                    <measurement group_id="O3" value="71.4" spread="14.01"/>
                    <measurement group_id="O4" value="69.7" spread="10.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 15 min PD, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.0" spread="6.61"/>
                    <measurement group_id="O2" value="69.4" spread="12.16"/>
                    <measurement group_id="O3" value="68.9" spread="12.19"/>
                    <measurement group_id="O4" value="74.8" spread="9.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 45 min PD, n=9, 6, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.8" spread="9.16"/>
                    <measurement group_id="O2" value="66.3" spread="11.88"/>
                    <measurement group_id="O3" value="66.6" spread="10.98"/>
                    <measurement group_id="O4" value="70.0" spread="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 1.5 hr PD, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.3" spread="7.86"/>
                    <measurement group_id="O2" value="64.0" spread="10.92"/>
                    <measurement group_id="O3" value="63.8" spread="8.96"/>
                    <measurement group_id="O4" value="67.7" spread="11.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 4 hr PD, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.1" spread="7.61"/>
                    <measurement group_id="O2" value="62.7" spread="7.74"/>
                    <measurement group_id="O3" value="62.6" spread="9.79"/>
                    <measurement group_id="O4" value="67.5" spread="7.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 8 hr PD, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.8" spread="6.83"/>
                    <measurement group_id="O2" value="71.0" spread="8.60"/>
                    <measurement group_id="O3" value="74.8" spread="8.91"/>
                    <measurement group_id="O4" value="73.8" spread="7.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 24 hr PD, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8" spread="7.00"/>
                    <measurement group_id="O2" value="75.6" spread="11.50"/>
                    <measurement group_id="O3" value="72.6" spread="8.97"/>
                    <measurement group_id="O4" value="70.8" spread="9.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum and Weighted Mean (0-4 Hour) Heart Rate at Days 1 and 7</title>
        <description>Maximum heart rate (Max HR) and weighted mean (WM) from 0-4 hour on Days 1 and 7 were derived. Max HR (0-4 h) is defined as the maximum heart rate attained within 0-4 h. The weighted mean HR (0-4 h) was derived by calculating the area under the curve, and then dividing the value by the relevant time interval. Each of the maximum and weighted mean (0-4h) endpoints for heart rate, was statistically analyzed using a mixed effects model. The terms treatment, baseline, day and any relevant interactions were considered in the model. Least squares means are adjusted for treatment, Baseline, day, treatment by Baseline and Baseline by day interaction, where Baseline is defined as the mean of the three pre-dose assessments.</description>
        <time_frame>Day 1 and Day 7</time_frame>
        <population>All Subjects Population (ASP). The number of participants presented represent those with data available at the time point being presented; however, all participants in the ASP without missing covariate information are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received either a single inhaled dose or four inhaled doses of matching placebo once daily (QD) for 7 days via a dry powder inhaler (DPI).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 UMEC 250 µg</title>
            <description>Participants received a single inhaled dose of umeclidinium (UMEC) 250 micrograms (µg) formulated with magnesium stearate (MgSt) QD for 7 days via a DPI.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 UMEC 250 µg in Error</title>
            <description>Participants received a single inhaled dose of UMEC 250 μg formulated with MgSt QD for 7 days via a DPI. These participants were to have been randomized to receive UMEC 1000 µg; however, they received UMEC 250 µg in error.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3 UMEC 1000 µg</title>
            <description>Participants received four inhaled doses of UMEC 250 μg (equivalent to 1000 μg) formulated with MgSt QD for 7 days via a DPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum and Weighted Mean (0-4 Hour) Heart Rate at Days 1 and 7</title>
          <description>Maximum heart rate (Max HR) and weighted mean (WM) from 0-4 hour on Days 1 and 7 were derived. Max HR (0-4 h) is defined as the maximum heart rate attained within 0-4 h. The weighted mean HR (0-4 h) was derived by calculating the area under the curve, and then dividing the value by the relevant time interval. Each of the maximum and weighted mean (0-4h) endpoints for heart rate, was statistically analyzed using a mixed effects model. The terms treatment, baseline, day and any relevant interactions were considered in the model. Least squares means are adjusted for treatment, Baseline, day, treatment by Baseline and Baseline by day interaction, where Baseline is defined as the mean of the three pre-dose assessments.</description>
          <population>All Subjects Population (ASP). The number of participants presented represent those with data available at the time point being presented; however, all participants in the ASP without missing covariate information are included in the analysis.</population>
          <units>Beats per minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, Max HR, n=9, 10, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.30" spread="2.009"/>
                    <measurement group_id="O2" value="70.56" spread="1.910"/>
                    <measurement group_id="O3" value="71.57" spread="1.924"/>
                    <measurement group_id="O4" value="75.79" spread="2.066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, Max HR, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.99" spread="1.917"/>
                    <measurement group_id="O2" value="70.24" spread="2.203"/>
                    <measurement group_id="O3" value="66.74" spread="1.964"/>
                    <measurement group_id="O4" value="77.69" spread="2.398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, WM, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.84" spread="1.582"/>
                    <measurement group_id="O2" value="63.62" spread="1.584"/>
                    <measurement group_id="O3" value="66.17" spread="1.514"/>
                    <measurement group_id="O4" value="70.00" spread="1.627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, WM, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.83" spread="1.682"/>
                    <measurement group_id="O2" value="64.98" spread="1.874"/>
                    <measurement group_id="O3" value="62.32" spread="1.698"/>
                    <measurement group_id="O4" value="71.89" spread="2.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.777</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.39</ci_lower_limit>
            <ci_upper_limit>7.91</ci_upper_limit>
            <estimate_desc>Day 1, Max HR</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.922</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.78</ci_lower_limit>
            <ci_upper_limit>7.28</ci_upper_limit>
            <estimate_desc>Day 7, Max HR</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.772</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.37</ci_lower_limit>
            <ci_upper_limit>8.91</ci_upper_limit>
            <estimate_desc>Day 1, Max HR</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.729</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.89</ci_lower_limit>
            <ci_upper_limit>3.39</ci_upper_limit>
            <estimate_desc>Day 7, Max HR</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.899</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.59</ci_lower_limit>
            <ci_upper_limit>13.39</ci_upper_limit>
            <estimate_desc>Day 1, Max HR</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.079</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.34</ci_lower_limit>
            <ci_upper_limit>15.05</ci_upper_limit>
            <estimate_desc>Day 7, Max HR</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.243</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.80</ci_lower_limit>
            <ci_upper_limit>4.34</ci_upper_limit>
            <estimate_desc>Day 1, WM</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.520</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.09</ci_lower_limit>
            <ci_upper_limit>5.40</ci_upper_limit>
            <estimate_desc>Day 7, WM</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.182</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.12</ci_lower_limit>
            <ci_upper_limit>6.77</ci_upper_limit>
            <estimate_desc>Day 1, WM</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.378</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.48</ci_lower_limit>
            <ci_upper_limit>2.45</ci_upper_limit>
            <estimate_desc>Day 7, WM</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.282</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.51</ci_lower_limit>
            <ci_upper_limit>10.81</ci_upper_limit>
            <estimate_desc>Day 1, WM</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.642</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.57</ci_lower_limit>
            <ci_upper_limit>12.54</ci_upper_limit>
            <estimate_desc>Day 7, WM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With the Indicated 12-lead Electrocardiogram (ECG) Values on Days 1 and 7</title>
        <description>The number of participants with normal (NL), abnormal not clinically significant (Abn NCS), and abnormal clinically significant (Abn CS) ECG findings, as well as those with unavailable results (NA) at pre-dose (PD1, PD2, PD3), and 15 min, 45 min, 1.5 hr, 4 hr, and 8 hr post-dose (PD) on Day 1 and at pre-dose (PD1, PD2, PD3), and 15 min, 45 min, 1.5 hr, 4 hr, 8 hr, and 24 hr post-dose on Day 7 are reported. The following are of potential clinical importance: absolute QTc interval &gt;450 milliseconds (msec); increase from Baseline QTc &gt;60 msec; PR interval &lt;110 and &gt;220 msec; QRS interval &lt;75 and &gt;110 msec. Clinical significance was based on the medical and scientific judgement of the investigator or qualified designee.</description>
        <time_frame>Day 1 (pre-dose and 15 min, 45 min, 1.5 hr, 4 hr, and 8 hr post-dose) and Day 7 (pre-dose and 15 min, 45 min, 1.5 hr, 4 hr, 8 hr, and 24 hr)</time_frame>
        <population>All Subjects Population. Only participants with data available at the indicated time points were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received either a single inhaled dose or four inhaled doses of matching placebo once daily (QD) for 7 days via a dry powder inhaler (DPI).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 UMEC 250 µg</title>
            <description>Participants received a single inhaled dose of umeclidinium (UMEC) 250 micrograms (µg) formulated with magnesium stearate (MgSt) QD for 7 days via a DPI.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 UMEC 250 µg in Error</title>
            <description>Participants received a single inhaled dose of UMEC 250 μg formulated with MgSt QD for 7 days via a DPI. These participants were to have been randomized to receive UMEC 1000 µg; however, they received UMEC 250 µg in error.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3 UMEC 1000 µg</title>
            <description>Participants received four inhaled doses of UMEC 250 μg (equivalent to 1000 μg) formulated with MgSt QD for 7 days via a DPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated 12-lead Electrocardiogram (ECG) Values on Days 1 and 7</title>
          <description>The number of participants with normal (NL), abnormal not clinically significant (Abn NCS), and abnormal clinically significant (Abn CS) ECG findings, as well as those with unavailable results (NA) at pre-dose (PD1, PD2, PD3), and 15 min, 45 min, 1.5 hr, 4 hr, and 8 hr post-dose (PD) on Day 1 and at pre-dose (PD1, PD2, PD3), and 15 min, 45 min, 1.5 hr, 4 hr, 8 hr, and 24 hr post-dose on Day 7 are reported. The following are of potential clinical importance: absolute QTc interval &gt;450 milliseconds (msec); increase from Baseline QTc &gt;60 msec; PR interval &lt;110 and &gt;220 msec; QRS interval &lt;75 and &gt;110 msec. Clinical significance was based on the medical and scientific judgement of the investigator or qualified designee.</description>
          <population>All Subjects Population. Only participants with data available at the indicated time points were summarized.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, PD1, NL, n=9, 10, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, PD1, Abn NCS, n=9, 10, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, PD1, Abn CS, n=9, 10, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, PD1, NA, n=9, 10, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, PD2, NL, n=9, 10, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, PD2, Abn NCS, n=9, 10, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, PD2, Abn CS, n=9, 10, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, PD2, NA, n=9, 10, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, PD3, NL, n=9, 10, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, PD3, Abn NCS, n=9, 10, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, PD3, Abn CS, 9, 10, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, PD3, NA, n=9, 10, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 15 min PD, NL, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 15 min PD, Abn NCS, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 15 min PD, Abn CS, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 15 min PD, NA, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 45 min PD, NL, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 45 min PD, Abn NCS, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 45 min PD, Abn CS, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 45 min PD, NA, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1.5 hr PD, NL, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1.5 hr PD, Abn NCS, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1.5 hr PD, Abn CS, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1.5 hr PD, NA, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4 hr PD, NL, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4 hr PD, Abn NCS, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4 hr PD, Abn CS, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4 hr PD, NA, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 8 hr PD, NL, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 8 hr PD, Abn NCS, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 8 hr PD, Abn CS, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 8 hr PD, NA, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, PD1, NL, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, PD1, Abn NCS, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, PD1, Abn CS, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, PD1, NA, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, PD2, NL, n=9, 7, 8, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, PD2, Abn NCS, n=9, 7, 8, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, PD2, Abn CS, n=9, 7, 8, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, PD2, NA, n=9, 7, 8, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, PD3, NL, n=9, 7, 8, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, PD3, Abn NCS, n=9, 7, 8, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, PD3, Abn CS, 9, 7, 8, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, PD3, NA, n=9, 7, 8, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 15 min PD, NL, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 15 min PD, Abn NCS, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 15 min PD, Abn CS, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 15 min PD, NA, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 45 min PD, NL, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 45 min PD, Abn NCS, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 45 min PD, Abn CS, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 45 min PD, NA, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 1.5 hr PD, NL, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 1.5 hr PD, Abn NCS, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 1.5 hr PD, Abn CS, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 1.5 hr PD, NA, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 4 hr PD, NL, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 4 hr PD, Abn NCS, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 4 hr PD, Abn CS, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 4 hr PD, NA, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 8 hr PD, NL, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 8 hr PD, Abn NCS, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 8 hr PD, Abn CS, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 8 hr PD, NA, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 24 hr PD, NL, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 24 hr PD, Abn NCS, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 24 hr PD, Abn CS, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 24 hr PD, NA, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal 24-hour Holter Findings at Screening and Day 7</title>
        <description>Twenty-four hour Holter ECG values were obtained at Screening and on Day 7. During the Screening procedure and study, standard Holter monitors were used (in order to exclude participants with underlying cardiac arrhythmogenicity). During the treatment periods, Holter monitors were only switched on immediately prior to dosing (up to 15 minutes pre-dose) so as to capture Holter ECG data from the 24 hour period following dosing. The following summary data were transcribed into the Case Report Form: Maximum and mean (0 to24 hour) heart rate; normal and aberrant beats and arrhythmias. Analysis of the Holter tapes was arranged by GlaxoSmithKline.The number of participants with normal (NL), abnormal not clinically significant (Abn NCS), and abnormal clinically significant (Abn CS) ECG findings, as well as those with unavailable results (NA) at Screening and Day 7, are reported. Clinical significance was based on the medical and scientific judgement of the investigator or qualified designee.</description>
        <time_frame>Screening and Day 7</time_frame>
        <population>All Subjects Population. Only participants with data available at the indicated time points were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received either a single inhaled dose or four inhaled doses of matching placebo once daily (QD) for 7 days via a dry powder inhaler (DPI).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 UMEC 250 µg</title>
            <description>Participants received a single inhaled dose of umeclidinium (UMEC) 250 micrograms (µg) formulated with magnesium stearate (MgSt) QD for 7 days via a DPI.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 UMEC 250 µg in Error</title>
            <description>Participants received a single inhaled dose of UMEC 250 μg formulated with MgSt QD for 7 days via a DPI. These participants were to have been randomized to receive UMEC 1000 µg; however, they received UMEC 250 µg in error.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3 UMEC 1000 µg</title>
            <description>Participants received four inhaled doses of UMEC 250 μg (equivalent to 1000 μg) formulated with MgSt QD for 7 days via a DPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal 24-hour Holter Findings at Screening and Day 7</title>
          <description>Twenty-four hour Holter ECG values were obtained at Screening and on Day 7. During the Screening procedure and study, standard Holter monitors were used (in order to exclude participants with underlying cardiac arrhythmogenicity). During the treatment periods, Holter monitors were only switched on immediately prior to dosing (up to 15 minutes pre-dose) so as to capture Holter ECG data from the 24 hour period following dosing. The following summary data were transcribed into the Case Report Form: Maximum and mean (0 to24 hour) heart rate; normal and aberrant beats and arrhythmias. Analysis of the Holter tapes was arranged by GlaxoSmithKline.The number of participants with normal (NL), abnormal not clinically significant (Abn NCS), and abnormal clinically significant (Abn CS) ECG findings, as well as those with unavailable results (NA) at Screening and Day 7, are reported. Clinical significance was based on the medical and scientific judgement of the investigator or qualified designee.</description>
          <population>All Subjects Population. Only participants with data available at the indicated time points were summarized.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening, NL, n=9 ,10, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening, Abn NCS, n=9 ,10, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening, Abn CS, n=9 ,10, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day7, NL, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day7, Abn NCS, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day7, Abn CS, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day7, NA, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum and Mean (0-24 Hour) Heart Rate From Holter Monitoring on Day 7</title>
        <description>Maximum heart rate (Max HR) and mean HR from 0-24 hour Holter monitoring on treatment Day 7 were derived. The analysis was adjusted for treatment and Baseline, where Baseline is defined as the corresponding summary measure (i.e., mean heart rate [0-24 hours] or maximum heart rate [0-24 hours]) from screening records.</description>
        <time_frame>Day 7</time_frame>
        <population>All Subjects Population. The number of participants presented represent those with data available at the time point being presented; however, all participants in the ASP without missing covariate information are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received either a single inhaled dose or four inhaled doses of matching placebo once daily (QD) for 7 days via a dry powder inhaler (DPI).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 UMEC 250 µg</title>
            <description>Participants received a single inhaled dose of umeclidinium (UMEC) 250 micrograms (µg) formulated with magnesium stearate (MgSt) QD for 7 days via a DPI.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 UMEC 250 µg in Error</title>
            <description>Participants received a single inhaled dose of UMEC 250 μg formulated with MgSt QD for 7 days via a DPI. These participants were to have been randomized to receive UMEC 1000 µg; however, they received UMEC 250 µg in error.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3 UMEC 1000 µg</title>
            <description>Participants received four inhaled doses of UMEC 250 μg (equivalent to 1000 μg) formulated with MgSt QD for 7 days via a DPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum and Mean (0-24 Hour) Heart Rate From Holter Monitoring on Day 7</title>
          <description>Maximum heart rate (Max HR) and mean HR from 0-24 hour Holter monitoring on treatment Day 7 were derived. The analysis was adjusted for treatment and Baseline, where Baseline is defined as the corresponding summary measure (i.e., mean heart rate [0-24 hours] or maximum heart rate [0-24 hours]) from screening records.</description>
          <population>All Subjects Population. The number of participants presented represent those with data available at the time point being presented; however, all participants in the ASP without missing covariate information are included in the analysis.</population>
          <units>Beats per minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Max HR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.19" spread="4.744"/>
                    <measurement group_id="O2" value="134.08" spread="5.810"/>
                    <measurement group_id="O3" value="127.48" spread="4.724"/>
                    <measurement group_id="O4" value="126.91" spread="5.785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean HR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.47" spread="1.896"/>
                    <measurement group_id="O2" value="75.94" spread="2.306"/>
                    <measurement group_id="O3" value="75.96" spread="1.888"/>
                    <measurement group_id="O4" value="76.75" spread="2.312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Forced Expiratory Volume in One Second (FEV1) at Screening and on Days 1 and 7</title>
        <description>FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 was measured at Screening, pre-dose, and 4 hours (hr) post-dose on Day 1 and Day 7. FEV1 tests were repeated until three technically acceptable measurements were made.</description>
        <time_frame>Screening, Day 1, and Day 7</time_frame>
        <population>All Subjects Population. Only participants with data available at the indicated time points were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received either a single inhaled dose or four inhaled doses of matching placebo once daily (QD) for 7 days via a dry powder inhaler (DPI).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 UMEC 250 µg</title>
            <description>Participants received a single inhaled dose of umeclidinium (UMEC) 250 micrograms (µg) formulated with magnesium stearate (MgSt) QD for 7 days via a DPI.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 UMEC 250 µg in Error</title>
            <description>Participants received a single inhaled dose of UMEC 250 μg formulated with MgSt QD for 7 days via a DPI. These participants were to have been randomized to receive UMEC 1000 µg; however, they received UMEC 250 µg in error.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3 UMEC 1000 µg</title>
            <description>Participants received four inhaled doses of UMEC 250 μg (equivalent to 1000 μg) formulated with MgSt QD for 7 days via a DPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Forced Expiratory Volume in One Second (FEV1) at Screening and on Days 1 and 7</title>
          <description>FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 was measured at Screening, pre-dose, and 4 hours (hr) post-dose on Day 1 and Day 7. FEV1 tests were repeated until three technically acceptable measurements were made.</description>
          <population>All Subjects Population. Only participants with data available at the indicated time points were summarized.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening, n=9, 10, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.556" spread="0.6315"/>
                    <measurement group_id="O2" value="1.253" spread="0.4338"/>
                    <measurement group_id="O3" value="1.562" spread="0.5066"/>
                    <measurement group_id="O4" value="1.364" spread="0.3504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, pre-dose, n=9, 10, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.294" spread="0.4642"/>
                    <measurement group_id="O2" value="1.059" spread="0.3509"/>
                    <measurement group_id="O3" value="1.443" spread="0.4840"/>
                    <measurement group_id="O4" value="1.289" spread="0.2968"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4 hr post-dose, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.309" spread="0.4333"/>
                    <measurement group_id="O2" value="1.250" spread="0.3934"/>
                    <measurement group_id="O3" value="1.565" spread="0.5858"/>
                    <measurement group_id="O4" value="1.534" spread="0.3389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, pre-dose, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.263" spread="0.4695"/>
                    <measurement group_id="O2" value="1.153" spread="0.4066"/>
                    <measurement group_id="O3" value="1.593" spread="0.5425"/>
                    <measurement group_id="O4" value="1.483" spread="0.3055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 4 hr post-dose, n=9, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.250" spread="0.5143"/>
                    <measurement group_id="O2" value="1.181" spread="0.3875"/>
                    <measurement group_id="O3" value="1.564" spread="0.5476"/>
                    <measurement group_id="O4" value="1.517" spread="0.2685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Number of Salbutamol Doses Taken Over the 7 -Day Study Period</title>
        <description>The total number of salbutamol doses taken per day was recorded by the participants in their dairy card over the entire 7-day treatment period. Diaries were reviewed by the Investigator when participants were admitted to the unit on Day 1, Day 7, and Day 8. Salbutamol was given as rescue medication, defined as a quick-relief or fast-acting medication that is given in addition to the investigational drug or placebo that can alleviate symptoms due to disease or lack of efficacy of the study treatment.</description>
        <time_frame>Day 1 to Day 7</time_frame>
        <population>All Subjects Population. Only those participants who took at least one dose of salbutamol were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received either a single inhaled dose or four inhaled doses of matching placebo once daily (QD) for 7 days via a dry powder inhaler (DPI).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 UMEC 250 µg</title>
            <description>Participants received a single inhaled dose of umeclidinium (UMEC) 250 micrograms (µg) formulated with magnesium stearate (MgSt) QD for 7 days via a DPI.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 UMEC 250 µg in Error</title>
            <description>Participants received a single inhaled dose of UMEC 250 μg formulated with MgSt QD for 7 days via a DPI. These participants were to have been randomized to receive UMEC 1000 µg; however, they received UMEC 250 µg in error.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3 UMEC 1000 µg</title>
            <description>Participants received four inhaled doses of UMEC 250 μg (equivalent to 1000 μg) formulated with MgSt QD for 7 days via a DPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Salbutamol Doses Taken Over the 7 -Day Study Period</title>
          <description>The total number of salbutamol doses taken per day was recorded by the participants in their dairy card over the entire 7-day treatment period. Diaries were reviewed by the Investigator when participants were admitted to the unit on Day 1, Day 7, and Day 8. Salbutamol was given as rescue medication, defined as a quick-relief or fast-acting medication that is given in addition to the investigational drug or placebo that can alleviate symptoms due to disease or lack of efficacy of the study treatment.</description>
          <population>All Subjects Population. Only those participants who took at least one dose of salbutamol were summarized.</population>
          <units>salbutamol doses</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Albumin, Total Protein, Hemoglobin, and Mean Corpuscle Hemoglobin Concentration (MCHC) Values on Day 1 and Day 7</title>
        <description>Blood samples were collected for the measurement of albumin, total protein, hemoglobin, and MCHC values pre-dose on Day 1 and Day 7.</description>
        <time_frame>Day 1 and Day 7</time_frame>
        <population>All Subjects Population. Only participants with data available at the indicated time points were summarized. Different participants may have been summarized for different parameters/at different time points (reflected by n=X, X, X, X in the category titles), so the overall number of participants summarized reflects everyone in the ASP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received either a single inhaled dose or four inhaled doses of matching placebo once daily (QD) for 7 days via a dry powder inhaler (DPI).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 UMEC 250 µg</title>
            <description>Participants received a single inhaled dose of umeclidinium (UMEC) 250 micrograms (µg) formulated with magnesium stearate (MgSt) QD for 7 days via a DPI.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 UMEC 250 µg in Error</title>
            <description>Participants received a single inhaled dose of UMEC 250 μg formulated with MgSt QD for 7 days via a DPI. These participants were to have been randomized to receive UMEC 1000 µg; however, they received UMEC 250 µg in error.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3 UMEC 1000 µg</title>
            <description>Participants received four inhaled doses of UMEC 250 μg (equivalent to 1000 μg) formulated with MgSt QD for 7 days via a DPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Albumin, Total Protein, Hemoglobin, and Mean Corpuscle Hemoglobin Concentration (MCHC) Values on Day 1 and Day 7</title>
          <description>Blood samples were collected for the measurement of albumin, total protein, hemoglobin, and MCHC values pre-dose on Day 1 and Day 7.</description>
          <population>All Subjects Population. Only participants with data available at the indicated time points were summarized. Different participants may have been summarized for different parameters/at different time points (reflected by n=X, X, X, X in the category titles), so the overall number of participants summarized reflects everyone in the ASP.</population>
          <units>Grams per liter (G/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin, Day 1, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.3" spread="3.43"/>
                    <measurement group_id="O2" value="43.9" spread="2.09"/>
                    <measurement group_id="O3" value="43.7" spread="2.16"/>
                    <measurement group_id="O4" value="44.1" spread="3.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, Day 7, n=8, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.1" spread="1.81"/>
                    <measurement group_id="O2" value="44.0" spread="1.15"/>
                    <measurement group_id="O3" value="43.8" spread="2.64"/>
                    <measurement group_id="O4" value="44.0" spread="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total protein, Day 1, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.4" spread="5.48"/>
                    <measurement group_id="O2" value="70.0" spread="3.24"/>
                    <measurement group_id="O3" value="69.9" spread="3.70"/>
                    <measurement group_id="O4" value="69.8" spread="3.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total protein, Day 7, n=8, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.6" spread="3.16"/>
                    <measurement group_id="O2" value="70.0" spread="2.16"/>
                    <measurement group_id="O3" value="71.0" spread="4.53"/>
                    <measurement group_id="O4" value="69.7" spread="3.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, Day 1, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152.2" spread="8.60"/>
                    <measurement group_id="O2" value="148.0" spread="14.19"/>
                    <measurement group_id="O3" value="147.4" spread="11.84"/>
                    <measurement group_id="O4" value="145.4" spread="16.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, Day 7, n=9, 6, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151.4" spread="7.80"/>
                    <measurement group_id="O2" value="145.8" spread="14.77"/>
                    <measurement group_id="O3" value="147.4" spread="13.71"/>
                    <measurement group_id="O4" value="143.5" spread="16.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC, Day 1, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="340.0" spread="6.10"/>
                    <measurement group_id="O2" value="338.7" spread="5.39"/>
                    <measurement group_id="O3" value="339.9" spread="5.49"/>
                    <measurement group_id="O4" value="337.2" spread="3.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC, Day 7, n=9, 6, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="337.6" spread="7.84"/>
                    <measurement group_id="O2" value="340.7" spread="5.20"/>
                    <measurement group_id="O3" value="337.4" spread="5.59"/>
                    <measurement group_id="O4" value="337.3" spread="5.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) Values on Day1 and Day 7</title>
        <description>Blood samples were collected for the measurement of ALP, ALT, AST, and GGT Pre-dose on Day 1 and Day 7.</description>
        <time_frame>Day 1 and Day 7</time_frame>
        <population>All Subjects Population. Only participants with data available at the indicated time points were summarized. Different participants may have been summarized for different parameters/at different time points (reflected by n=X, X, X, X in the category titles), so the overall number of participants summarized reflects everyone in the ASP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received either a single inhaled dose or four inhaled doses of matching placebo once daily (QD) for 7 days via a dry powder inhaler (DPI).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 UMEC 250 µg</title>
            <description>Participants received a single inhaled dose of umeclidinium (UMEC) 250 micrograms (µg) formulated with magnesium stearate (MgSt) QD for 7 days via a DPI.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 UMEC 250 µg in Error</title>
            <description>Participants received a single inhaled dose of UMEC 250 μg formulated with MgSt QD for 7 days via a DPI. These participants were to have been randomized to receive UMEC 1000 µg; however, they received UMEC 250 µg in error.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3 UMEC 1000 µg</title>
            <description>Participants received four inhaled doses of UMEC 250 μg (equivalent to 1000 μg) formulated with MgSt QD for 7 days via a DPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) Values on Day1 and Day 7</title>
          <description>Blood samples were collected for the measurement of ALP, ALT, AST, and GGT Pre-dose on Day 1 and Day 7.</description>
          <population>All Subjects Population. Only participants with data available at the indicated time points were summarized. Different participants may have been summarized for different parameters/at different time points (reflected by n=X, X, X, X in the category titles), so the overall number of participants summarized reflects everyone in the ASP.</population>
          <units>International units per liter (IU/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALP, Day 1, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.0" spread="20.20"/>
                    <measurement group_id="O2" value="76.8" spread="15.11"/>
                    <measurement group_id="O3" value="69.0" spread="18.43"/>
                    <measurement group_id="O4" value="63.8" spread="20.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP, Day 7, n=8, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.6" spread="20.18"/>
                    <measurement group_id="O2" value="73.1" spread="16.16"/>
                    <measurement group_id="O3" value="71.1" spread="16.47"/>
                    <measurement group_id="O4" value="67.7" spread="18.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Day 1, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="10.36"/>
                    <measurement group_id="O2" value="15.6" spread="6.06"/>
                    <measurement group_id="O3" value="24.2" spread="9.66"/>
                    <measurement group_id="O4" value="18.6" spread="9.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Day 7, n=8, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" spread="6.85"/>
                    <measurement group_id="O2" value="15.6" spread="7.11"/>
                    <measurement group_id="O3" value="29.8" spread="12.81"/>
                    <measurement group_id="O4" value="20.7" spread="9.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Day 1, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" spread="5.90"/>
                    <measurement group_id="O2" value="18.9" spread="3.48"/>
                    <measurement group_id="O3" value="26.5" spread="10.28"/>
                    <measurement group_id="O4" value="22.6" spread="8.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Day 7, n=8, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3" spread="6.16"/>
                    <measurement group_id="O2" value="19.4" spread="4.31"/>
                    <measurement group_id="O3" value="30.7" spread="12.16"/>
                    <measurement group_id="O4" value="25.2" spread="8.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, Day 1, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3" spread="20.62"/>
                    <measurement group_id="O2" value="28.0" spread="13.19"/>
                    <measurement group_id="O3" value="61.0" spread="56.20"/>
                    <measurement group_id="O4" value="37.7" spread="31.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, Day 7, n=8, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9" spread="18.88"/>
                    <measurement group_id="O2" value="24.7" spread="6.78"/>
                    <measurement group_id="O3" value="66.0" spread="68.81"/>
                    <measurement group_id="O4" value="39.8" spread="32.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Direct Bilirubin, Total Bilirubin, and Creatinine Values on Day 1 and Day 7</title>
        <description>Blood samples were collected for the measurement of direct bilirubin, total bilirubin, and creatinine at pre-dose on Day 1 and Day 7.</description>
        <time_frame>Day 1 and Day 7</time_frame>
        <population>All Subjects Population. Only participants with data available at the indicated time points were summarized. Different participants may have been summarized for different parameters/at different time points (reflected by n=X, X, X, X in the category titles), so the overall number of participants summarized reflects everyone in the ASP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received either a single inhaled dose or four inhaled doses of matching placebo once daily (QD) for 7 days via a dry powder inhaler (DPI).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 UMEC 250 µg</title>
            <description>Participants received a single inhaled dose of umeclidinium (UMEC) 250 micrograms (µg) formulated with magnesium stearate (MgSt) QD for 7 days via a DPI.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 UMEC 250 µg in Error</title>
            <description>Participants received a single inhaled dose of UMEC19 250 μg formulated with MgSt QD for 7 days via a DPI. These participants were to have been randomized to receive UMEC 1000 µg; however, they received UMEC 250 µg in error.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3 UMEC 1000 µg</title>
            <description>Participants received four inhaled doses of UMEC 250 μg (equivalent to 1000 μg) formulated with MgSt QD for 7 days via a DPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Direct Bilirubin, Total Bilirubin, and Creatinine Values on Day 1 and Day 7</title>
          <description>Blood samples were collected for the measurement of direct bilirubin, total bilirubin, and creatinine at pre-dose on Day 1 and Day 7.</description>
          <population>All Subjects Population. Only participants with data available at the indicated time points were summarized. Different participants may have been summarized for different parameters/at different time points (reflected by n=X, X, X, X in the category titles), so the overall number of participants summarized reflects everyone in the ASP.</population>
          <units>Micromoles per liter (µmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Direct bilirubin, Day 1, n=6, 9, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="1.97"/>
                    <measurement group_id="O2" value="1.7" spread="0.50"/>
                    <measurement group_id="O3" value="2.0" spread="1.15"/>
                    <measurement group_id="O4" value="NA">Per protocol, data were collected for participants in all 3 cohorts; however, Cohort 3 data were not fully reported to GSK by the vendor. This oversight was recently detected, and this summary will be amended once remedial work has been completed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bilirubin, Day 7, n=5, 7, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="1.41"/>
                    <measurement group_id="O2" value="2.0" spread="0.58"/>
                    <measurement group_id="O3" value="2.2" spread="0.67"/>
                    <measurement group_id="O4" value="NA">Per protocol, data were collected for participants in all 3 cohorts; however, Cohort 3 data were not fully reported to GSK by the vendor. This oversight was recently detected, and this summary will be amended once remedial work has been completed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin, Day 1, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="4.44"/>
                    <measurement group_id="O2" value="8.2" spread="1.20"/>
                    <measurement group_id="O3" value="10.9" spread="4.01"/>
                    <measurement group_id="O4" value="10.2" spread="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin, Day 7, n=8, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="4.03"/>
                    <measurement group_id="O2" value="9.9" spread="2.27"/>
                    <measurement group_id="O3" value="10.8" spread="3.11"/>
                    <measurement group_id="O4" value="11.0" spread="3.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, Day 1, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2" spread="12.15"/>
                    <measurement group_id="O2" value="84.3" spread="15.64"/>
                    <measurement group_id="O3" value="80.1" spread="14.26"/>
                    <measurement group_id="O4" value="87.0" spread="33.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, Day 7, n=8, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.8" spread="10.53"/>
                    <measurement group_id="O2" value="80.1" spread="14.37"/>
                    <measurement group_id="O3" value="82.6" spread="12.83"/>
                    <measurement group_id="O4" value="93.0" spread="39.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Calcium, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) Values on Day 1 and Day 7</title>
        <description>Blood samples were collected for the measurement of calcium, glucose, potassium, sodium, and urea/BUN pre-dose on Day 1 and Day 7.</description>
        <time_frame>Day 1 and Day 7</time_frame>
        <population>All Subjects Population. Only participants with data available at the indicated time points were summarized. Different participants may have been summarized for different parameters/at different time points (reflected by n=X, X, X, X in the category titles), so the overall number of participants summarized reflects everyone in the ASP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received either a single inhaled dose or four inhaled doses of matching placebo once daily (QD) for 7 days via a dry powder inhaler (DPI).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 UMEC 250 µg</title>
            <description>Participants received a single inhaled dose of umeclidinium (UMEC) 250 micrograms (µg) formulated with magnesium stearate (MgSt) QD for 7 days via a DPI.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 UMEC 250 µg in Error</title>
            <description>Participants received a single inhaled dose of UMEC 250 μg formulated with MgSt QD for 7 days via a DPI. These participants were to have been randomized to receive UMEC 1000 µg; however, they received UMEC 250 µg in error.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3 UMEC 1000 µg</title>
            <description>Participants received four inhaled doses of UMEC 250 μg (equivalent to 1000 μg) formulated with MgSt QD for 7 days via a DPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Calcium, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) Values on Day 1 and Day 7</title>
          <description>Blood samples were collected for the measurement of calcium, glucose, potassium, sodium, and urea/BUN pre-dose on Day 1 and Day 7.</description>
          <population>All Subjects Population. Only participants with data available at the indicated time points were summarized. Different participants may have been summarized for different parameters/at different time points (reflected by n=X, X, X, X in the category titles), so the overall number of participants summarized reflects everyone in the ASP.</population>
          <units>Millimoles per liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calcium, Day 1, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.317" spread="0.0622"/>
                    <measurement group_id="O2" value="2.329" spread="0.0697"/>
                    <measurement group_id="O3" value="2.342" spread="0.1215"/>
                    <measurement group_id="O4" value="2.311" spread="0.0807"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, Day 7, n=8, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.320" spread="0.0454"/>
                    <measurement group_id="O2" value="2.321" spread="0.0308"/>
                    <measurement group_id="O3" value="2.370" spread="0.1411"/>
                    <measurement group_id="O4" value="2.343" spread="0.0631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, Day 1, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.16" spread="0.937"/>
                    <measurement group_id="O2" value="5.13" spread="0.524"/>
                    <measurement group_id="O3" value="5.38" spread="0.751"/>
                    <measurement group_id="O4" value="5.26" spread="0.921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, Day 7, n=8, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.25" spread="0.746"/>
                    <measurement group_id="O2" value="5.10" spread="0.792"/>
                    <measurement group_id="O3" value="5.84" spread="0.948"/>
                    <measurement group_id="O4" value="5.42" spread="0.717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, Day 1, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.67" spread="0.472"/>
                    <measurement group_id="O2" value="4.70" spread="0.485"/>
                    <measurement group_id="O3" value="4.50" spread="0.579"/>
                    <measurement group_id="O4" value="4.36" spread="0.364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, Day 7, n=8, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.58" spread="0.276"/>
                    <measurement group_id="O2" value="4.74" spread="0.431"/>
                    <measurement group_id="O3" value="4.48" spread="0.519"/>
                    <measurement group_id="O4" value="4.45" spread="0.428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, Day 1, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.8" spread="2.59"/>
                    <measurement group_id="O2" value="140.6" spread="1.51"/>
                    <measurement group_id="O3" value="140.6" spread="2.27"/>
                    <measurement group_id="O4" value="139.6" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, Day 7, n=8, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.4" spread="2.88"/>
                    <measurement group_id="O2" value="140.0" spread="1.15"/>
                    <measurement group_id="O3" value="140.2" spread="2.44"/>
                    <measurement group_id="O4" value="139.2" spread="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN, Day 1, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.92" spread="1.730"/>
                    <measurement group_id="O2" value="5.29" spread="0.842"/>
                    <measurement group_id="O3" value="5.77" spread="1.854"/>
                    <measurement group_id="O4" value="5.72" spread="2.440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN, Day 7, n=8, 7, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.15" spread="1.032"/>
                    <measurement group_id="O2" value="5.51" spread="0.691"/>
                    <measurement group_id="O3" value="5.70" spread="1.562"/>
                    <measurement group_id="O4" value="5.88" spread="3.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Basophil, Eosinophil, Lymphocyte, Monocyte, Total Neutrophil (ANC: Absolute Neutrophil Count), Platelet, and White Blood Cell (WBC) Count Values on Day 1 and Day 7</title>
        <description>Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, total neutrophils (ANC), platelets, and white blood cell (WBC) count pre-dose on Day 1 and Day 7.</description>
        <time_frame>Day 1 and Day 7</time_frame>
        <population>All Subjects Population. Only participants with data available at the indicated time points were summarized. Different participants may have been summarized for different parameters/at different time points (reflected by n=X, X, X, X in the category titles), so the overall number of participants summarized reflects everyone in the ASP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received either a single inhaled dose or four inhaled doses of matching placebo once daily (QD) for 7 days via a dry powder inhaler (DPI).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 UMEC 250 µg</title>
            <description>Participants received a single inhaled dose of umeclidinium (UMEC) 250 micrograms (µg) formulated with magnesium stearate (MgSt) QD for 7 days via a DPI.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 UMEC 250 µg in Error</title>
            <description>Participants received a single inhaled dose of UMEC 250 μg formulated with MgSt QD for 7 days via a DPI. These participants were to have been randomized to receive UMEC 1000 µg; however, they received UMEC 250 µg in error.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3 UMEC 1000 µg</title>
            <description>Participants received four inhaled doses of UMEC 250 μg (equivalent to 1000 μg) formulated with MgSt QD for 7 days via a DPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Basophil, Eosinophil, Lymphocyte, Monocyte, Total Neutrophil (ANC: Absolute Neutrophil Count), Platelet, and White Blood Cell (WBC) Count Values on Day 1 and Day 7</title>
          <description>Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, total neutrophils (ANC), platelets, and white blood cell (WBC) count pre-dose on Day 1 and Day 7.</description>
          <population>All Subjects Population. Only participants with data available at the indicated time points were summarized. Different participants may have been summarized for different parameters/at different time points (reflected by n=X, X, X, X in the category titles), so the overall number of participants summarized reflects everyone in the ASP.</population>
          <units>10^9 cells per liter (GI/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils, Day 1, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Per protocol, data were collected for participants in all 3 cohorts; however, data were not fully reported to GSK by the vendor. This oversight was recently detected, and this summary will be amended once remedial work has been completed.</measurement>
                    <measurement group_id="O2" value="NA">Per protocol, data were collected for participants in all 3 cohorts; however, data were not fully reported to GSK by the vendor. This oversight was recently detected, and this summary will be amended once remedial work has been completed.</measurement>
                    <measurement group_id="O3" value="NA">Per protocol, data were collected for participants in all 3 cohorts; however, data were not fully reported to GSK by the vendor. This oversight was recently detected, and this summary will be amended once remedial work has been completed.</measurement>
                    <measurement group_id="O4" value="NA">Per protocol, data were collected for participants in all 3 cohorts; however, data were not fully reported to GSK by the vendor. This oversight was recently detected, and this summary will be amended once remedial work has been completed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils, Day 7, n=9, 6, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Per protocol, data were collected for participants in all 3 cohorts; however, data were not fully reported to GSK by the vendor. This oversight was recently detected, and this summary will be amended once remedial work has been completed.</measurement>
                    <measurement group_id="O2" value="NA">Per protocol, data were collected for participants in all 3 cohorts; however, data were not fully reported to GSK by the vendor. This oversight was recently detected, and this summary will be amended once remedial work has been completed.</measurement>
                    <measurement group_id="O3" value="NA">Per protocol, data were collected for participants in all 3 cohorts; however, data were not fully reported to GSK by the vendor. This oversight was recently detected, and this summary will be amended once remedial work has been completed.</measurement>
                    <measurement group_id="O4" value="NA">Per protocol, data were collected for participants in all 3 cohorts; however, data were not fully reported to GSK by the vendor. This oversight was recently detected, and this summary will be amended once remedial work has been completed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, Day 1, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.248" spread="0.1052"/>
                    <measurement group_id="O2" value="0.319" spread="0.1968"/>
                    <measurement group_id="O3" value="0.352" spread="0.2951"/>
                    <measurement group_id="O4" value="0.144" spread="0.0910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, Day 7, n=9, 6, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.232" spread="0.0793"/>
                    <measurement group_id="O2" value="0.280" spread="0.1754"/>
                    <measurement group_id="O3" value="0.312" spread="0.2672"/>
                    <measurement group_id="O4" value="0.153" spread="0.0911"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, Day 1, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Per protocol, data were collected for participants in all 3 cohorts; however, data were not fully reported to GSK by the vendor. This oversight was recently detected, and this summary will be amended once remedial work has been completed.</measurement>
                    <measurement group_id="O2" value="NA">Per protocol, data were collected for participants in all 3 cohorts; however, data were not fully reported to GSK by the vendor. This oversight was recently detected, and this summary will be amended once remedial work has been completed.</measurement>
                    <measurement group_id="O3" value="NA">Per protocol, data were collected for participants in all 3 cohorts; however, data were not fully reported to GSK by the vendor. This oversight was recently detected, and this summary will be amended once remedial work has been completed.</measurement>
                    <measurement group_id="O4" value="NA">Per protocol, data were collected for participants in all 3 cohorts; however, data were not fully reported to GSK by the vendor. This oversight was recently detected, and this summary will be amended once remedial work has been completed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, Day 7, n=9, 6, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Per protocol, data were collected for participants in all 3 cohorts; however, data were not fully reported to GSK by the vendor. This oversight was recently detected, and this summary will be amended once remedial work has been completed.</measurement>
                    <measurement group_id="O2" value="NA">Per protocol, data were collected for participants in all 3 cohorts; however, data were not fully reported to GSK by the vendor. This oversight was recently detected, and this summary will be amended once remedial work has been completed.</measurement>
                    <measurement group_id="O3" value="NA">Per protocol, data were collected for participants in all 3 cohorts; however, data were not fully reported to GSK by the vendor. This oversight was recently detected, and this summary will be amended once remedial work has been completed.</measurement>
                    <measurement group_id="O4" value="NA">Per protocol, data were collected for participants in all 3 cohorts; however, data were not fully reported to GSK by the vendor. This oversight was recently detected, and this summary will be amended once remedial work has been completed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, Day 1, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.510" spread="0.1348"/>
                    <measurement group_id="O2" value="0.614" spread="0.3648"/>
                    <measurement group_id="O3" value="0.607" spread="0.1594"/>
                    <measurement group_id="O4" value="0.506" spread="0.2010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, Day 7, n=9, 6, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.448" spread="0.1313"/>
                    <measurement group_id="O2" value="0.562" spread="0.2791"/>
                    <measurement group_id="O3" value="0.657" spread="0.1993"/>
                    <measurement group_id="O4" value="0.503" spread="0.2430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANC, Day 1, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.233" spread="2.0968"/>
                    <measurement group_id="O2" value="5.306" spread="1.3061"/>
                    <measurement group_id="O3" value="4.244" spread="1.3332"/>
                    <measurement group_id="O4" value="4.946" spread="2.3879"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANC, Day 7, n=9, 6, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.706" spread="1.8634"/>
                    <measurement group_id="O2" value="5.023" spread="1.4969"/>
                    <measurement group_id="O3" value="4.067" spread="1.0184"/>
                    <measurement group_id="O4" value="5.323" spread="1.8539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, Day 1, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="278.1" spread="66.25"/>
                    <measurement group_id="O2" value="238.2" spread="39.71"/>
                    <measurement group_id="O3" value="254.7" spread="51.04"/>
                    <measurement group_id="O4" value="222.4" spread="43.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, Day 7, n=9, 6, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271.8" spread="53.73"/>
                    <measurement group_id="O2" value="256.8" spread="36.71"/>
                    <measurement group_id="O3" value="255.1" spread="61.42"/>
                    <measurement group_id="O4" value="250.3" spread="59.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC count, Day 1, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.06" spread="2.220"/>
                    <measurement group_id="O2" value="8.52" spread="2.153"/>
                    <measurement group_id="O3" value="7.11" spread="1.692"/>
                    <measurement group_id="O4" value="7.56" spread="2.572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC count, Day 7, n=9, 6, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.49" spread="2.211"/>
                    <measurement group_id="O2" value="8.15" spread="2.519"/>
                    <measurement group_id="O3" value="7.13" spread="1.564"/>
                    <measurement group_id="O4" value="7.87" spread="2.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Corpuscle Hemoglobin (MCH) Values on Day 1 and Day 7</title>
        <description>Blood samples were collected for the measurement of MCH pre-dose on Day 1 and Day 7.</description>
        <time_frame>Day 1 and Day 7</time_frame>
        <population>All Subjects Population. Only participants with data available at the indicated time points were summarized. Different participants may have been summarized for different parameters/at different time points (reflected by n=X, X, X, X in the category titles), so the overall number of participants summarized reflects everyone in the ASP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received either a single inhaled dose or four inhaled doses of matching placebo once daily (QD) for 7 days via a dry powder inhaler (DPI).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 UMEC 250 µg</title>
            <description>Participants received a single inhaled dose of umeclidinium (UMEC) 250 micrograms (µg) formulated with magnesium stearate (MgSt) QD for 7 days via a DPI.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 UMEC 250 µg in Error</title>
            <description>Participants received a single inhaled dose of UMEC 250 μg formulated with MgSt QD for 7 days via a DPI. These participants were to have been randomized to receive UMEC 1000 µg; however, they received UMEC 250 µg in error.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3 UMEC 1000 µg</title>
            <description>Participants received four inhaled doses of UMEC 250 μg (equivalent to 1000 μg) formulated with MgSt QD for 7 days via a DPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Corpuscle Hemoglobin (MCH) Values on Day 1 and Day 7</title>
          <description>Blood samples were collected for the measurement of MCH pre-dose on Day 1 and Day 7.</description>
          <population>All Subjects Population. Only participants with data available at the indicated time points were summarized. Different participants may have been summarized for different parameters/at different time points (reflected by n=X, X, X, X in the category titles), so the overall number of participants summarized reflects everyone in the ASP.</population>
          <units>picograms/cell (pg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.92" spread="1.711"/>
                    <measurement group_id="O2" value="32.44" spread="2.371"/>
                    <measurement group_id="O3" value="31.25" spread="1.978"/>
                    <measurement group_id="O4" value="31.70" spread="1.859"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, n=9, 6, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.71" spread="1.661"/>
                    <measurement group_id="O2" value="32.20" spread="2.871"/>
                    <measurement group_id="O3" value="31.22" spread="1.999"/>
                    <measurement group_id="O4" value="31.95" spread="2.146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Corpuscle Volume (MCV) Values on Day 1 and Day 7</title>
        <description>Blood samples were collected for the measurement of MCV pre-dose on Day 1 and Day 7.</description>
        <time_frame>Day 1 and Day 7</time_frame>
        <population>All Subjects Population. Only participants with data available at the indicated time points were summarized. Different participants may have been summarized for different parameters/at different time points (reflected by n=X, X, X, X in the category titles), so the overall number of participants summarized reflects everyone in the ASP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received either a single inhaled dose or four inhaled doses of matching placebo once daily (QD) for 7 days via a dry powder inhaler (DPI).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 UMEC 250 µg</title>
            <description>Participants received a single inhaled dose of umeclidinium (UMEC) 250 micrograms (µg) formulated with magnesium stearate (MgSt) QD for 7 days via a DPI.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 UMEC 250 µg in Error</title>
            <description>Participants received a single inhaled dose of UMEC 250 μg formulated with MgSt QD for 7 days via a DPI. These participants were to have been randomized to receive UMEC 1000 µg; however, they received UMEC 250 µg in error.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3 UMEC 1000 µg</title>
            <description>Participants received four inhaled doses of UMEC 250 μg (equivalent to 1000 μg) formulated with MgSt QD for 7 days via a DPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Corpuscle Volume (MCV) Values on Day 1 and Day 7</title>
          <description>Blood samples were collected for the measurement of MCV pre-dose on Day 1 and Day 7.</description>
          <population>All Subjects Population. Only participants with data available at the indicated time points were summarized. Different participants may have been summarized for different parameters/at different time points (reflected by n=X, X, X, X in the category titles), so the overall number of participants summarized reflects everyone in the ASP.</population>
          <units>10^-15 liters (femtoliters)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, n=9, 9, 10, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.9" spread="3.66"/>
                    <measurement group_id="O2" value="95.9" spread="7.06"/>
                    <measurement group_id="O3" value="91.9" spread="4.93"/>
                    <measurement group_id="O4" value="94.0" spread="5.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, n=9, 6, 9, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.0" spread="3.50"/>
                    <measurement group_id="O2" value="94.5" spread="7.12"/>
                    <measurement group_id="O3" value="92.6" spread="5.34"/>
                    <measurement group_id="O4" value="94.8" spread="5.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean AUC(0-2), AUC(0-8), and AUC(0-t) of UMEC on Day 1 and Day 7</title>
        <description>Area under the concentration-time (AUC) curve from time zero (pre-dose) to 2 hours (AUC[0-2]), from time zero to 8 hours (AUC[0-8]), from time zero to the last time of a quantifiable concentration of UMEC (AUC[0-t]) on Day 1 and Day 7 were measured. AUC is a measure of systemic exposure. Blood samples were collected pre-dose and 5 min, 15 min, 30 min, 1 hr, 2 hr, 4 hr, and 8 hr post-dose on Day 1 and Day 7. Also, a 24 hr blood sample was collected on Day 7.</description>
        <time_frame>Day 1 and Day 7: pre-dose, and 5 min, 15 min, 30 min, 1 hr, 2 hr, 4 hr, and 8 hr post-dose; 24 hr post-dose on Day 7</time_frame>
        <population>Pharmacokinetic (PK) Population: participants (par.) in the ASP for whom a PK sample was obtained and analyzed. Different par. may have been summarized for different parameters/at different time points (reflected by n=X, X, X, X in the category titles), so the overall number of par. summarized reflects everyone in the PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received either a single inhaled dose or four inhaled doses of matching placebo once daily (QD) for 7 days via a dry powder inhaler (DPI).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 UMEC 250 µg</title>
            <description>Participants received a single inhaled dose of umeclidinium (UMEC) 250 micrograms (µg) formulated with magnesium stearate (MgSt) QD for 7 days via a DPI.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 UMEC 250 µg in Error</title>
            <description>Participants received a single inhaled dose of UMEC 250 μg formulated with MgSt QD for 7 days via a DPI. These participants were to have been randomized to receive UMEC 1000 µg; however, they received UMEC 250 µg in error.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3 UMEC 1000 µg</title>
            <description>Participants received four inhaled doses of UMEC 250 μg (equivalent to 1000 μg) formulated with MgSt QD for 7 days via a DPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean AUC(0-2), AUC(0-8), and AUC(0-t) of UMEC on Day 1 and Day 7</title>
          <description>Area under the concentration-time (AUC) curve from time zero (pre-dose) to 2 hours (AUC[0-2]), from time zero to 8 hours (AUC[0-8]), from time zero to the last time of a quantifiable concentration of UMEC (AUC[0-t]) on Day 1 and Day 7 were measured. AUC is a measure of systemic exposure. Blood samples were collected pre-dose and 5 min, 15 min, 30 min, 1 hr, 2 hr, 4 hr, and 8 hr post-dose on Day 1 and Day 7. Also, a 24 hr blood sample was collected on Day 7.</description>
          <population>Pharmacokinetic (PK) Population: participants (par.) in the ASP for whom a PK sample was obtained and analyzed. Different par. may have been summarized for different parameters/at different time points (reflected by n=X, X, X, X in the category titles), so the overall number of par. summarized reflects everyone in the PK Population.</population>
          <units>hr * nanograms per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-2), Day 1, n=0, 8, 9, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.19675" spread="19.7"/>
                    <measurement group_id="O3" value="0.08134" spread="108.0"/>
                    <measurement group_id="O4" value="0.95719" spread="233.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-2), Day 7, n=0, 6, 8, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.31951" spread="51.6"/>
                    <measurement group_id="O3" value="0.15527" spread="66.5"/>
                    <measurement group_id="O4" value="1.92508" spread="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-8), Day 1, n=0, 0, 0, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA">Due to non-quantifiable data at the lower dose (250 µg) at later time points, data for this parameter could not be calculated.</measurement>
                    <measurement group_id="O3" value="NA">Due to non-quantifiable data at the lower dose (250 µg) at later time points, data for this parameter could not be calculated.</measurement>
                    <measurement group_id="O4" value="2.029" spread="69.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-8), Day 7, n=0, 0, 0, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA">Due to non-quantifiable data at the lower dose (250 µg) at later time points, data for this parameter could not be calculated.</measurement>
                    <measurement group_id="O3" value="NA">Due to non-quantifiable data at the lower dose (250 µg) at later time points, data for this parameter could not be calculated.</measurement>
                    <measurement group_id="O4" value="3.320" spread="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-t), Day 1, n=0, 8, 9, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.26071" spread="39.1"/>
                    <measurement group_id="O3" value="0.03614" spread="1707.8"/>
                    <measurement group_id="O4" value="0.93299" spread="5820.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-t), Day 7, n=0, 6, 8, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.55514" spread="113.2"/>
                    <measurement group_id="O3" value="0.30526" spread="134.3"/>
                    <measurement group_id="O4" value="4.86204" spread="42.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of UMEC on Day 1 and Day 7</title>
        <description>Cmax is defined as the maximum observed concentration of UMEC and was measured on Day 1 and Day 7. Blood samples were collected pre-dose and 5 min, 15 min, 30 min, 1 hr, 2 hr, 4 hr, and 8 hr post-dose on Day 1 and Day 7. Also, a 24 hr blood sample was collected on Day 7.</description>
        <time_frame>Day 1 and Day 7: pre-dose, and 5 min, 15 min, 30 min, 1 hr, 2 hr, 4 hr, and 8 hr post-dose; 24 hr post-dose on Day 7</time_frame>
        <population>PK Population. Only participants with data available at the indicated time points were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received either a single inhaled dose or four inhaled doses of matching placebo once daily (QD) for 7 days via a dry powder inhaler (DPI).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 UMEC 250 µg</title>
            <description>Participants received a single inhaled dose of umeclidinium (UMEC) 250 micrograms (µg) formulated with magnesium stearate (MgSt) QD for 7 days via a DPI.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 UMEC 250 µg in Error</title>
            <description>Participants received a single inhaled dose of UMEC 250 μg formulated with MgSt QD for 7 days via a DPI. These participants were to have been randomized to receive UMEC 1000 µg; however, they received UMEC 250 µg in error.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3 UMEC 1000 µg</title>
            <description>Participants received four inhaled doses of UMEC 250 μg (equivalent to 1000 μg) formulated with MgSt QD for 7 days via a DPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of UMEC on Day 1 and Day 7</title>
          <description>Cmax is defined as the maximum observed concentration of UMEC and was measured on Day 1 and Day 7. Blood samples were collected pre-dose and 5 min, 15 min, 30 min, 1 hr, 2 hr, 4 hr, and 8 hr post-dose on Day 1 and Day 7. Also, a 24 hr blood sample was collected on Day 7.</description>
          <population>PK Population. Only participants with data available at the indicated time points were summarized.</population>
          <units>nanograms per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, n=0, 8, 9, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.21654" spread="32.0"/>
                    <measurement group_id="O3" value="0.07915" spread="147.6"/>
                    <measurement group_id="O4" value="1.52835" spread="53.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, n=0, 6, 8, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.33206" spread="58.3"/>
                    <measurement group_id="O3" value="0.16448" spread="74.2"/>
                    <measurement group_id="O4" value="2.75864" spread="60.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax and Tlastof UMEC on Day 1 and Day 7</title>
        <description>Tmax is defined as the time to reach the observed maximum concentration, and tlast is defined as the time of the last quantifiable concentration of UMEC; both were measured on Day 1 and Day 7. Blood samples were collected pre-dose, and 5 min, 15 min, 30 min, 1 hr, 2 hr, 4 hr, and 8 hr post-dose on Day 1 and Day 7. Also, a 24 hr blood sample was collected on Day 7.</description>
        <time_frame>Day 1 and Day 7: pre-dose, and 5 min, 15 min, 30 min, 1 hr, 2 hr, 4 hr, and 8 hr post-dose; 24 hr post-dose on Day 7</time_frame>
        <population>PK Population. Only participants with data available at the indicated time points were summarized. Different participants may have been summarized for different parameters/at different time points (reflected by n=X, X, X, X in the category titles), so the overall number of participants summarized reflects everyone in the PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received either a single inhaled dose or four inhaled doses of matching placebo once daily (QD) for 7 days via a dry powder inhaler (DPI).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 UMEC 250 µg</title>
            <description>Participants received a single inhaled dose of umeclidinium (UMEC) 250 micrograms (µg) formulated with magnesium stearate (MgSt) QD for 7 days via a DPI.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 UMEC 250 µg in Error</title>
            <description>Participants received a single inhaled dose of UMEC 250 μg formulated with MgSt QD for 7 days via a DPI. These participants were to have been randomized to receive UMEC 1000 µg; however, they received UMEC 250 µg in error.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3 UMEC 1000 µg</title>
            <description>Participants received four inhaled doses of UMEC 250 μg (equivalent to 1000 μg) formulated with MgSt QD for 7 days via a DPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax and Tlastof UMEC on Day 1 and Day 7</title>
          <description>Tmax is defined as the time to reach the observed maximum concentration, and tlast is defined as the time of the last quantifiable concentration of UMEC; both were measured on Day 1 and Day 7. Blood samples were collected pre-dose, and 5 min, 15 min, 30 min, 1 hr, 2 hr, 4 hr, and 8 hr post-dose on Day 1 and Day 7. Also, a 24 hr blood sample was collected on Day 7.</description>
          <population>PK Population. Only participants with data available at the indicated time points were summarized. Different participants may have been summarized for different parameters/at different time points (reflected by n=X, X, X, X in the category titles), so the overall number of participants summarized reflects everyone in the PK Population.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>tmax, Day 1, n=0, 8, 8, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.080" lower_limit="0.08" upper_limit="0.50"/>
                    <measurement group_id="O3" value="0.250" lower_limit="0.08" upper_limit="0.28"/>
                    <measurement group_id="O4" value="0.250" lower_limit="0.08" upper_limit="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tmax, Day 7, n=0, 6, 8, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.080" lower_limit="0.02" upper_limit="0.25"/>
                    <measurement group_id="O3" value="0.165" lower_limit="0.08" upper_limit="0.32"/>
                    <measurement group_id="O4" value="0.240" lower_limit="0.07" upper_limit="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tlast, Day 1, n=0, 8, 8, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="4.000" lower_limit="2.00" upper_limit="8.12"/>
                    <measurement group_id="O3" value="2.000" lower_limit="0.08" upper_limit="4.00"/>
                    <measurement group_id="O4" value="8.000" lower_limit="0.08" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tlast, Day 7, n=0, 6, 8, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="6.000" lower_limit="2.00" upper_limit="27.05"/>
                    <measurement group_id="O3" value="6.015" lower_limit="2.00" upper_limit="24.00"/>
                    <measurement group_id="O4" value="24.010" lower_limit="24.00" upper_limit="24.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ae(0-4), Ae(0-8), Ae(0-12), and Ae(0-24) of UMEC on Day 1 and Day 7</title>
        <description>Urinary recovery of unchanged drug (UMEC) within the first 8, 12, and 24 hours (Ae[0-8], Ae[0-12], and Ae[0-24], respectively) on Day 1 and within the first 4, 8, 12, and 24 hours (Ae[0-4], Ae[0-8], Ae[0-12], and Ae[0-24], respectively) on Day 7 was estimated. Urine samples were collected from 0-8 hours (hr), 8-12 hr, and 12-24 hr on Day 1 and from 0-4 hr, 4-8 hr, 8-12 hr, and 12-24 hr on Day 7.</description>
        <time_frame>From 0-8 hours (hr), 8-12 hr, and 12-24 hr on Day 1; from 0-4 hr, 4-8 hr, 8-12 hr, and 12-24 hr on Day 7</time_frame>
        <population>PK Population. Only participants with data available at the indicated time points were summarized. Different participants may have been summarized for different parameters/at different time points (reflected by n=X, X, X, X in the category titles), so the overall number of participants summarized reflects everyone in the PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received either a single inhaled dose or four inhaled doses of matching placebo once daily (QD) for 7 days via a dry powder inhaler (DPI).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 UMEC 250 µg</title>
            <description>Participants received a single inhaled dose of umeclidinium (UMEC) 250 micrograms (µg) formulated with magnesium stearate (MgSt) QD for 7 days via a DPI.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 UMEC 250 µg in Error</title>
            <description>Participants received a single inhaled dose of UMEC 250 μg formulated with MgSt QD for 7 days via a DPI. These participants were to have been randomized to receive UMEC 1000 µg; however, they received UMEC 250 µg in error.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3 UMEC 1000 µg</title>
            <description>Participants received four inhaled doses of UMEC 250 μg (equivalent to 1000 μg) formulated with MgSt QD for 7 days via a DPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Ae(0-4), Ae(0-8), Ae(0-12), and Ae(0-24) of UMEC on Day 1 and Day 7</title>
          <description>Urinary recovery of unchanged drug (UMEC) within the first 8, 12, and 24 hours (Ae[0-8], Ae[0-12], and Ae[0-24], respectively) on Day 1 and within the first 4, 8, 12, and 24 hours (Ae[0-4], Ae[0-8], Ae[0-12], and Ae[0-24], respectively) on Day 7 was estimated. Urine samples were collected from 0-8 hours (hr), 8-12 hr, and 12-24 hr on Day 1 and from 0-4 hr, 4-8 hr, 8-12 hr, and 12-24 hr on Day 7.</description>
          <population>PK Population. Only participants with data available at the indicated time points were summarized. Different participants may have been summarized for different parameters/at different time points (reflected by n=X, X, X, X in the category titles), so the overall number of participants summarized reflects everyone in the PK Population.</population>
          <units>nanograms (ng)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ae(0-4), Day 7, n=0, 5, 8, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1223.6" spread="77.8"/>
                    <measurement group_id="O3" value="669.5" spread="129.8"/>
                    <measurement group_id="O4" value="11854.5" spread="65.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ae(0-8), Day 1, n=0, 6, 7, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1756.0" spread="46.6"/>
                    <measurement group_id="O3" value="755.9" spread="101.5"/>
                    <measurement group_id="O4" value="13435.9" spread="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ae(0-8), Day 7, n=0, 5, 8, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="3115.8" spread="27.2"/>
                    <measurement group_id="O3" value="1430.8" spread="49.6"/>
                    <measurement group_id="O4" value="19319.3" spread="50.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ae(0-12), Day 1, n=0, 6, 7, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2022.3" spread="41.2"/>
                    <measurement group_id="O3" value="921.7" spread="97.6"/>
                    <measurement group_id="O4" value="16069.2" spread="56.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ae(0-12), Day 7, n=0, 5, 8, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="4165.6" spread="15.3"/>
                    <measurement group_id="O3" value="1960.5" spread="53.6"/>
                    <measurement group_id="O4" value="23496.1" spread="44.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ae(0-24), Day 1, n=0, 6, 7, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2503.5" spread="38.0"/>
                    <measurement group_id="O3" value="1420.3" spread="130.9"/>
                    <measurement group_id="O4" value="19552.7" spread="47.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ae(0-24), Day 7, n=0, 5, 8, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="5606.2" spread="15.3"/>
                    <measurement group_id="O3" value="2984.5" spread="52.9"/>
                    <measurement group_id="O4" value="32140.0" spread="36.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fe(0-4), Fe(0-8), Fe(0-12), and Fe(0-24) of UMEC on Day 1 and Day 7</title>
        <description>The fraction of the total dose excreted (Fe) in each interval was estimated as the urinary recovery of unchanged drug (Ae) per dose. Urine samples were collected from 0-8 hours (hr), 8-12 hr, and 12-24 hr on Day 1 and from 0-4 hr, 4-8 hr, 8-12 hr, and 12-24 hr on Day 7.</description>
        <time_frame>From 0-8 hours (hr), 8-12 hr, and 12-24 hr on Day 1; from 0-4 hr, 4-8 hr, 8-12 hr, and 12-24 hr on Day 7</time_frame>
        <population>PK Population: Only participants with data available at the indicated time points were summarized. Different participants may have been summarized for different parameters/at different time points (reflected by n=X, X, X, X in the category titles), so the overall number of participants summarized reflects everyone in the PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received either a single inhaled dose or four inhaled doses of matching placebo once daily (QD) for 7 days via a dry powder inhaler (DPI).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 UMEC 250 µg</title>
            <description>Participants received a single inhaled dose of umeclidinium (UMEC) 250 micrograms (µg) formulated with magnesium stearate (MgSt) QD for 7 days via a DPI.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 UMEC 250 µg in Error</title>
            <description>Participants received a single inhaled dose of UMEC 250 μg formulated with MgSt QD for 7 days via a DPI. These participants were to have been randomized to receive UMEC 1000 µg; however, they received UMEC 250 µg in error.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3 UMEC 1000 µg</title>
            <description>Participants received four inhaled doses of UMEC 250 μg (equivalent to 1000 μg) formulated with MgSt QD for 7 days via a DPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Fe(0-4), Fe(0-8), Fe(0-12), and Fe(0-24) of UMEC on Day 1 and Day 7</title>
          <description>The fraction of the total dose excreted (Fe) in each interval was estimated as the urinary recovery of unchanged drug (Ae) per dose. Urine samples were collected from 0-8 hours (hr), 8-12 hr, and 12-24 hr on Day 1 and from 0-4 hr, 4-8 hr, 8-12 hr, and 12-24 hr on Day 7.</description>
          <population>PK Population: Only participants with data available at the indicated time points were summarized. Different participants may have been summarized for different parameters/at different time points (reflected by n=X, X, X, X in the category titles), so the overall number of participants summarized reflects everyone in the PK Population.</population>
          <units>Percentage of dose administered</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fe(0-4), Day 7, n=0, 5, 8, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.58" spread="0.35"/>
                    <measurement group_id="O3" value="0.37" spread="0.30"/>
                    <measurement group_id="O4" value="1.35" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe(0-8), Day 1, n=0, 6, 8, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.76" spread="0.35"/>
                    <measurement group_id="O3" value="0.34" spread="0.28"/>
                    <measurement group_id="O4" value="1.49" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe(0-8), Day 7, n=0, 5, 8, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.28" spread="0.30"/>
                    <measurement group_id="O3" value="0.62" spread="0.26"/>
                    <measurement group_id="O4" value="2.10" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe(0-12), Day 1, n=0, 6, 8, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.87" spread="0.38"/>
                    <measurement group_id="O3" value="0.41" spread="0.32"/>
                    <measurement group_id="O4" value="1.78" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe(0-12), Day 7, n=0, 5, 8, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.68" spread="0.25"/>
                    <measurement group_id="O3" value="0.86" spread="0.36"/>
                    <measurement group_id="O4" value="2.52" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe(0-24), Day 1, n=0, 6, 8, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.06" spread="0.41"/>
                    <measurement group_id="O3" value="0.70" spread="0.61"/>
                    <measurement group_id="O4" value="2.12" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe(0-24), Day 7, n=0, 5, 8, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2.26" spread="0.33"/>
                    <measurement group_id="O3" value="1.31" spread="0.54"/>
                    <measurement group_id="O4" value="3.38" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Clearance of UMEC on Day 1 and Day 7</title>
        <description>Renal clearance was calculated as the urinary recovery of unchanged drug from time zero to time x (Ae[0-x])/area under concentration from time zero to time x (AUC[0-x]) for the longest period of time after dosing when both could be accurately determined (where x is either 8, 12, or 24). Urine samples were collected from 0-8 hours (hr), 8-12 hr, and 12-24 hr on Day 1 and from 0-4 hr, 4-8 hr, 8-12 hr, and 12-24 hr on Day 7.</description>
        <time_frame>From 0-8 hours (hr), 8-12 hr, and 12-24 hr on Day 1; from 0-4 hr, 4-8 hr, 8-12 hr, and 12-24 hr on Day 7</time_frame>
        <population>PK Population. Only participants with data available at the indicated time points were summarized. Different participants may have been summarized for different parameters/at different time points (reflected by n=X, X, X, X in the category titles), so the overall number of participants summarized reflects everyone in the PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received either a single inhaled dose or four inhaled doses of matching placebo once daily (QD) for 7 days via a dry powder inhaler (DPI).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 UMEC 250 µg</title>
            <description>Participants received a single inhaled dose of umeclidinium (UMEC) 250 micrograms (µg) formulated with magnesium stearate (MgSt) QD for 7 days via a DPI.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 UMEC 250 µg in Error</title>
            <description>Participants received a single inhaled dose of UMEC 250 μg formulated with MgSt QD for 7 days via a DPI. These participants were to have been randomized to receive UMEC 1000 µg; however, they received UMEC 250 µg in error.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3 UMEC 1000 µg</title>
            <description>Participants received four inhaled doses of UMEC 250 μg (equivalent to 1000 μg) formulated with MgSt QD for 7 days via a DPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance of UMEC on Day 1 and Day 7</title>
          <description>Renal clearance was calculated as the urinary recovery of unchanged drug from time zero to time x (Ae[0-x])/area under concentration from time zero to time x (AUC[0-x]) for the longest period of time after dosing when both could be accurately determined (where x is either 8, 12, or 24). Urine samples were collected from 0-8 hours (hr), 8-12 hr, and 12-24 hr on Day 1 and from 0-4 hr, 4-8 hr, 8-12 hr, and 12-24 hr on Day 7.</description>
          <population>PK Population. Only participants with data available at the indicated time points were summarized. Different participants may have been summarized for different parameters/at different time points (reflected by n=X, X, X, X in the category titles), so the overall number of participants summarized reflects everyone in the PK Population.</population>
          <units>Liters/hour (L/hr)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, n=0, 1, 0, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="6.5229">A dispersion cannot be calculated for a single participant.</measurement>
                    <measurement group_id="O3" value="NA">Due to non-quantifiable data at the lower dose (250 µg) at later time points, data for this parameter could not be calculated.</measurement>
                    <measurement group_id="O4" value="5.6173" spread="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, n=0, 4, 6, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2.5923" spread="103.6"/>
                    <measurement group_id="O3" value="4.0826" spread="19.3"/>
                    <measurement group_id="O4" value="6.6104" spread="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine Half Life (t1/2) of UMEC on Day 7</title>
        <description>Urine half life (t1/2) of UMEC on Day 7 was estimated. Urine samples were collected from 0-4 hours (hr), 4-8 hr, 8-12 hr, and 12-24 hr on Day 7.</description>
        <time_frame>From 0-4 hours (hr), 4-8 hr, 8-12 hr, and 12-24 hr on Day 7</time_frame>
        <population>PK Population. Only participants with data available at the indicated time points were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received either a single inhaled dose or four inhaled doses of matching placebo once daily (QD) for 7 days via a dry powder inhaler (DPI).</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 UMEC 250 µg</title>
            <description>Participants received a single inhaled dose of umeclidinium (UMEC) 250 micrograms (µg) formulated with magnesium stearate (MgSt) QD for 7 days via a DPI.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 UMEC 250 µg in Error</title>
            <description>Participants received a single inhaled dose of UMEC 250 μg formulated with MgSt QD for 7 days via a DPI. These participants were to have been randomized to receive UMEC 1000 µg; however, they received UMEC 250 µg in error.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3 UMEC 1000 µg</title>
            <description>Participants received four inhaled doses of UMEC 250 μg (equivalent to 1000 μg) formulated with MgSt QD for 7 days via a DPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Half Life (t1/2) of UMEC on Day 7</title>
          <description>Urine half life (t1/2) of UMEC on Day 7 was estimated. Urine samples were collected from 0-4 hours (hr), 4-8 hr, 8-12 hr, and 12-24 hr on Day 7.</description>
          <population>PK Population. Only participants with data available at the indicated time points were summarized.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="5.785" spread="39.4"/>
                    <measurement group_id="O3" value="8.299" spread="37.3"/>
                    <measurement group_id="O4" value="7.643" spread="33.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>On-treatment serious adverse events (SAEs) and non-serious AEs (events occurring between the start of investigational product and follow-up contact) were collected from the start of study medication to the end of the treatment period (up to study day 12).</time_frame>
      <desc>On-treatment SAEs and non-serious AEs were collected in members of the All Subjects Population, comprised of all participants who received at least one dose of study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received either a single inhaled dose or four inhaled doses of matching placebo once daily (QD) for 7 days via a dry powder inhaler (DPI).</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1 UMEC 250 µg</title>
          <description>Participants received a single inhaled dose of umeclidinium (UMEC) 250 micrograms (µg) formulated with magnesium stearate (MgSt) QD for 7 days via a DPI.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 2 UMEC 250 µg in Error</title>
          <description>Participants received a single inhaled dose of UMEC 250 μg formulated with MgSt QD for 7 days via a DPI. These participants were to have been randomized to receive UMEC 1000 µg; however, they received UMEC 250 µg in error.</description>
        </group>
        <group group_id="E4">
          <title>Cohort 3 UMEC 1000 µg</title>
          <description>Participants received four inhaled doses of UMEC 250 μg (equivalent to 1000 μg) formulated with MgSt QD for 7 days via a DPI.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Absess jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Blood glucose abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Impaired fasting glucose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Subject 303 and Subject 317 correspond to the same participant who was randomized and dosed on two separate occasions. This participant has been counted as two separate participants on all the outputs.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

